Quarterlytics / Axcelis

Axcelis

acls · NASDAQ
Claim this profile
Ticker acls
Exchange NASDAQ
Sector
Industry
Employees 501-1000
← All annual reports
FY2010 Annual Report · Axcelis
Sign in to download
Loading PDF…
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K

(Mark  One)
(cid:2)

ANNUAL REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

(cid:3)

For the fiscal year ended December 31, 2010
TRANSITION REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from 

 to 
Commission file number 000-30941
AXCELIS TECHNOLOGIES,  INC.
(Exact name of registrant as specified  in its  charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

34-1818596
(IRS Employer Identification No.)

108 Cherry Hill Drive
Beverly, Massachusetts 01915
(Address of principal executive offices)  (zip code)

(978)  787-4000
(Registrant’s telephone number, including  area code)

Securities registered pursuant  to Section  12(b) of  the  Act:

Title of each class

Name of each  exchange  on which  registered

Common Stock, $.001 par value
Preferred Share Purchase Rights

The Nasdaq Stock  Market LLC

Securities registered pursuant to  Section  12(g) of  the  Act:
None

Indicate by check mark if the registrant is a  well-known  seasoned issuer, as  defined in  Rule  405 of the  Securities

Act. Yes (cid:3) No (cid:2)

Indicate by check mark if the registrant  is  not required  to  file  reports pursuant  to  Section 13  or  Section 15(d) of  the

Act. Yes (cid:3) No (cid:2)

Indicate by check mark whether the  registrant  (1)  has filed  all reports  required to be filed by Section  13  or  15(d) of

the Securities Exchange Act of 1934 during  the preceding 12  months  (or  for  such shorter period that the registrant was
required to file such reports), and (2)  has been  subject to such filing  requirements for  the past  90  days. Yes  (cid:2) No  (cid:3)

Indicate by checkmark whether the registrant  has  submitted electronically  and  posted on  its  corporate  Web site,  of
any,  every Interactive Data File required to be submitted and  posted  pursuant  to  Rule  405 of  Regulation S-T  during  the
preceding 12 months (or for such shorter period that  the  registrant  was required  to  submit  and post  such
files). Yes (cid:3) No (cid:3)

Indicate by check mark if disclosure of delinquent  filers  pursuant to Item 405  of  Regulation  S-K is  not  contained

herein, and will not be contained, to the best of  registrant’s  knowledge, in  definitive  proxy or  information statements
incorporated by reference  in  Part III  of this  Form 10-K or  any amendment  to  this  Form 10-K. (cid:3)

Indicate by check mark whether the registrant  is a large  accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See  the  definitions  of  ‘‘large  accelerated  filer,’’ ‘‘accelerated filer’’ and  ‘‘smaller
reporting company’’  in Rule  12b-2  of  the  Exchange Act.
Large accelerated filer (cid:3) Accelerated filer (cid:3) Non-accelerated  filer (cid:3) Smaller reporting  company (cid:2)

(Do not check if a smaller
reporting company)
Indicate by check mark whether  the registrant is  a shell  company (as  defined in Rule 12b-2 of the Act). Yes (cid:3) No (cid:2)

Aggregate market value of the voting stock held  by non-affiliates  of  the  registrant  as of June 30,  2010: $159,832,246

Number of shares outstanding of the registrant’s  Common  Stock, $0.001  par value,  as of March  14,  2011:

106,012,734.

Portions of the definitive Proxy Statement for  Axcelis  Technologies, Inc.’s  Annual  Meeting  of  Stockholders to be

held on April 26, 2011 are incorporated  by reference  into  Part III  of  this  Form  10-K.

Documents incorporated by reference:

Item 1. Business.

Overview of Our Business

PART I

Axcelis Technologies, Inc. (‘‘Axcelis,’’ the Company,’’  ‘‘we,’’ ‘‘us,’’ or ‘‘our’’) designs, manufactures

and services ion implantation, dry strip  and other processing equipment used in the fabrication of
semiconductor chips. We sell to leading  semiconductor chip manufacturers worldwide. The  ion
implantation business comprised approximately 84.4% of  our revenue in  2010 with the  remaining  15.6%
of revenue derived from our dry strip  and other processing systems.  In addition to equipment,  we
provide extensive aftermarket service  and  support, including spare parts,  equipment upgrades,
maintenance services and customer training.

Axcelis, which was incorporated in Delaware in 1995, is headquartered in Beverly, Massachusetts.

We  maintain an Internet site at http://www.axcelis.com. We  make available free of charge on and
through this website our annual reports on Form  10-K, quarterly reports on  Form 10-Q, current  reports
on Form 8-K, and amendments to those reports filed  or furnished  pursuant to Section 13(a) or  15(d) of
the Exchange Act as soon as reasonably practicable after we electronically file  such material with,  or
furnish it to, the Securities and Exchange Commission.  Our website and the information contained
therein or connected thereto shall not be deemed to be incorporated into  this Form 10-K.

Industry Overview

Semiconductor chips, also known as integrated  circuits, are  used  in personal computers,

telecommunication equipment, digital consumer electronics,  wireless communication  products and other
applications. Types of semiconductor  chips include  memory chips (which store and retrieve
information), microprocessors (logic devices which process  information) and ‘‘system on chip’’ devices
(which have both logic and memory features). Most  semiconductor  chips are built  on a wafer of silicon
of either 200mm (8 inches) or 300mm (12 inches) in diameter. Each semiconductor  chip is made up  of
millions of tiny transistors or ‘‘switches’’  to control the  functions of the  device. Transistors are  created
in the silicon wafer by introducing various precisely placed impurities into  the silicon in specific
patterns. The process steps in the formation of transistors are  traditionally referred to as
‘‘front-end-of-line.’’ The ‘‘back-end-of-line’’ process steps  connect the transistors and other components
together through several overlapping  layers of  metal wires, known  as interconnect, creating a complete
circuit. Each layer of metal interconnect  must be separated  by a non-conductive or insulating material
called inter-level dielectric. Each layer  that is added is selectively patterned to all previous  layers
through a process called photolithography.

Semiconductor chip manufacturers utilize many different types of equipment  in the making  of

integrated circuits. There are over 300 process steps utilizing over 50  different types of process tools
required in the making of a single device  like a microprocessor.  Semiconductor chip manufacturers
seek efficiency improvements through increased  throughput,  equipment  utilization and  higher
manufacturing yields. Capacity is added  by increasing the amount of manufacturing equipment in
existing fabrication facilities and by constructing new  fabrication facilities.  Periodically  the
semiconductor industry adopts a larger  silicon  wafer  size to achieve  lower manufacturing  costs.
Semiconductor manufacturers can produce more chips on  a  larger wafer, thus reducing the  overall
manufacturing cost per chip. For example, the  use of 200mm  wafers in production began at the  end of
the 1980s. The migration from 200mm to 300mm  began  at the  end  of the 1990s. The majority of wafer
fabrication facilities today are using wafers with a  diameter of 300mm. In 2010, Axcelis derived 87.2%
of total systems revenue (a component of  product revenue) from sales of 300mm equipment.

The customer base is also changing. Given the magnitude  of the investment needed to build  a new

wafer fabrication facility (often referred to as a ‘‘fab’’), which  can be over  $4 billion  for a  new

1

300mm fab, many customers are entering into partnerships  to  offset the  cost of technology  development
and manufacturing. In addition, many  chip  developers  outsource all  or part of their chip manufacturing
requirements to contract manufacturers,  known as foundries.  Foundries are significant purchasers of
semiconductor manufacturing equipment.

Historically, the semiconductor industry has grown on  an annual basis. However, the industry has

also been highly cyclical, as global chip production  capacities successively  exceed,  then lag behind,
global  chip demand. When chip demand  is high, and inventories low,  chip  manufacturers  add capacity
though capital equipment purchases. Given the  difficulties of forecasting and  calibrating chip demand
and production capacity, the industry periodically experiences excess chip inventories  and softening  chip
prices. Our customers react with muted  capital  spending, lowering the demand for our equipment.
Changes in consumer and business demand for  products in  which chips are used also affect the
industry.

During  the last six months of 2007 through 2009 challenging market conditions severely limited our

ability to increase sales and market share. During this period, adverse market conditions such  as credit
constriction, higher unemployment, lower corporate earnings, lower business investment and lower
consumer spending severely impacted many  technology manufacturers and significantly lowered the
demand for our products. A successful semiconductor equipment manufacturer must not only provide
some of the most technically complex products  manufactured in the world  but also  must  design its
business to thrive during the inevitable  low points in the cycle. During 2010  the Company benefited
from improved market conditions and  increased  capacity utilization at customers’ manufacturing
facilities. Industry forecasts project this  positive trend to continue into 2011.

Axcelis’ Strategy

Our mission and vision is to:

• Ensure our customers’ success by providing enabling semiconductor  manufacturing and support

solutions that deliver the best performance at  the lowest total cost of ownership.

• Achieve and maintain market share leadership in ion  implantation and  dry  strip.

• Deliver profitability and positive cash flow through the industry cycles to maximize shareholder

and employee value.

Operationally, we manage our business based on three  main tenets:

• technology leadership,

• operational excellence, and

• customer partnerships.

We  have continued to invest in research and development through  the industry cycles to assure our

products meet the needs of our customers.  We continue  to  add to our  portfolio  of patents and
unpatented proprietary technology to  ensure that our investment  in technology leadership is translated
into unique product advantages. We take  pride in  our  scientists  and engineers who  comprise over
one-third of our workforce. We strive for  operational excellence by  focusing on ways to lower our
manufacturing and design costs and to improve our delivery  times to our  customers. Finally, we have
grown and improved our customer support infrastructure and have established Global Customer Teams
and a focused account management structure  to  strengthen our  customer relationships  and increase
customer satisfaction.

2

Ion Implantation Systems

Ion implantation is a principal step in the transistor formation cycle  of the semiconductor

manufacturing process. An ion implanter  is  a large, technically  advanced machine that injects dopants
such as arsenic, boron or phosphorus into a silicon wafer. These dopants  are ionized and therefore
have electric charges. With an electric charge they  can be manipulated, moved  and accelerated with
electric and magnetic fields. Ion implanters use  these fields to create a beam of ions  with a precisely
defined amount of energy (ranging between several  hundred and three million electron-volts) and with
a precisely defined amount of beam current (ranging from  microamps  to  milliamps).  Certain areas of
the silicon wafer are blocked off by a polymer material known as  photoresist, which  acts  as a ‘‘stencil’’
to pattern devices so that the dopants  will only enter the wafer where needed.  The dopants change the
electrical properties of the silicon wafer  to create the active components of  a chip, called the
transistors. Typical process flows require twenty implant  steps, with the most advanced processes
requiring thirty or more. Each implant  step is  characterized by  four key parameters: dopant type, dose
(amount of dopant), energy (depth into  the silicon)  and tilt (angle  of  wafer  relative to the  ion beam).

In order to cover the wide range of implant steps,  three different types of  implanters have  been

developed, each designed to cover a specific range of  applications, primarily  defined by dose and
energy. The three traditional implanter types are referred to as medium current, high current and  high
energy:

• Medium current (mid dose) implanters  are the original model of  ion implanter, with mid to low-
range energy and dose capability. These implanters are single  wafer  systems in which only one
wafer at a time is slowly moved in front  of the ion beam.

• High current (high dose) implanters were the second type of  implanter to emerge, having low

energy capability and high dose range. High current  implanters were initially designed  as ‘‘multi
wafer’’ or ‘‘batch’’ tools for maximum  productivity, processing multiple  wafers  at the same time.
To address smaller device geometries and provide high tilt, single wafer high current  implanters
now dominate the sector.

• High energy implanters emerged to address  the need for deeper implants  with a high  energy

range and low dose. High energy implanters are available in both multi wafer and single wafer
architectures.

Axcelis offers a complete line of high energy, high current and medium current  implanters for all

application requirements.

• High Energy Implant. Axcelis is a market leader in high energy ion  implanters. Our  single wafer
tool for high energy applications, the Optima  XE, was released in  the fourth  quarter  of  2007
and  upgraded to the Optima XEx in  2009. The Optima XEx combines Axcelis’ production-
proven RF Linac high energy, spot beam technology with  a  high-speed, state-of-the-art single
wafer endstation, enabling unmatched throughput. Axcelis’ advanced spot beam ensures that all
points across the wafer see the same  beam at the  same beam angle, resulting in exceptional
process control and maximum yield. We expect  to  maintain  our leadership  in the high  energy
segment through sales of our multi wafer high energy systems and  the Optima XEx.

• High Current Implant. We introduced our single wafer Optima HD product (for high current
applications) in 2006, which was upgraded to the  Optima HDx in 2009. We  use the term ‘‘high
dose’’ or ‘‘HD’’ in connection with this product  because the Optima HD fulfills all traditional
high current requirements while extending beyond  traditional high current energy and dose
ranges. In order to maximize utilization and flexibility, the Optima HD can  process  some
traditional mid current implants. In addition, the Optima HD is  extendable into ultra-low  energy
applications to satisfy future process requirements including  leakage current performance.  The
Optima HD also supports molecular and hydrogen implant applications including dual poly  gate

3

and silicon-on-insulator applications to improve device speed and performance. With the  Optima
HDx, Axcelis is regaining market share  in high  current lost when customers  shifted from multi
wafer to single wafer tools.

• Medium Current Implant. With the introduction of the Optima MD in 2005,  Axcelis re-entered
the medium current market segment, which we had  not  participated  in since 2001.  We refer to
this  product as ‘‘mid dose’’ or ‘‘MD’’ because it  has energy  and  dose capabilities which  extend
beyond the traditional medium current space  into  traditional  high current and  high energy
spaces. Axcelis has continued to develop medium current  technology and  has plans to introduce
next generation products in the future.

We  believe the Optima products will  continue to meet  customer demand  for advantages in

productivity, simplicity, process performance  and  technical  extendibility.

Dry Strip

In the process steps prior to ion implantation, a light sensitive, polymer-based liquid  called

photoresist is spread in a uniformly thin film on the wafer. Through a process known as
photolithography, the photoresist is developed into  a pattern  like a stencil. Once the  subsequent
implant processes and etch steps (in  which the  top layer of the surface  of  the wafer  not  covered by
photoresist is removed) are completed, the photoresist is no longer necessary  and must be removed.
The primary means of removing photoresist  and  residue  is a process called  ‘‘dry  strip’’  or ‘‘ashing.’’ Our
dry strip machines, also called ‘‘ashers,’’  use microwave and radio  frequency energy to turn process
gases into plasma,  which then acts to  ‘‘clean’’ the surface of  the  wafer  by removing the  photoresist and
unwanted residue.

Axcelis offers a full line of dry strip tools  that cover the entire  range of customer applications. Our
newest product, the Integra RS, was  introduced in 2009 and brings significantly  higher productivity and
flexibility to Axcelis’ already proven advanced dry strip  process capabilities.  The  Integra RS’s unique
multi-chamber design includes paired-chamber process  modules that  can run  production  recipes  with
the highest throughputs available for  leading edge memory and  logic devices.  Each of the  chamber
pairs can operate independently, giving users the choice of running different cleaning recipes
simultaneously or performing maintenance on  one  module while the others continue to operate. This
flexibility makes the system ideal for  a variety  of advanced cleaning  applications  in a high  volume
manufacturing environment. The platform also includes technology required to address cleaning
challenges at emerging transistor device nodes,  such as those associated with advanced source/drain
formation and high-k/metal-gate structures.

We  believe our dry strip products and technology will continue  to  meet customer demand  for

advantages in productivity, process performance  and  technical  extendibility.

Other Processing Systems

Axcelis also provides aftermarket support for the installed  base of thermal processing and

photostabilization/curing systems manufactured by  Axcelis. In 2007 Axcelis ceased further development
of these  product lines.

Photostabilization/Curing Systems

In some manufacturing processes, the photoresist  stencil material

spread on the wafer must be hardened or ‘‘cured.’’ Axcelis’  curing (also known  as photostabilization)
systems use proprietary ultraviolet light sources to cure the photoresist so the  material  maintains  the
desired pattern during the subsequent  implant processes  and etch steps.

The photostabilization and curing market has remained a  small segment.  In past  years,  Axcelis has
explored growth opportunities for this  product line in curing and drying new  low-k dielectric materials.
To date, broad adoption of such materials has not occurred. In the fourth quarter of 2007,  Axcelis

4

determined that the current and near  term  market  opportunity  for the curing product  line did not
justify continuing investment in these  products. As a result, Axcelis decided to cease future  product
development in curing to focus on profitable growth within the company’s core  ion implant  and dry
strip businesses.

Thermal  Processing Systems At a number of points during the manufacturing process, silicon
wafers need to be heated rapidly, often to 900 degrees centigrade or higher, in  order  to  complete
chemical or electronic reactions. This  heating process  is referred to as rapid thermal processing, or
RTP. Our thermal processing systems employ  a patented design to process a  single wafer in a  hot  wall
vertical reactor. This technology differs from most  other thermal processing equipment, which regulate
temperature through a lamp-based system.  The RTP market  is dominated by a single major  competitor
and, while the Axcelis RTP systems have  technological  advantages for certain applications, our
penetration into the market remains  low. In  the third quarter of 2007, Axcelis determined that the
current and near term market opportunity for the RTP product line  did not justify continuing
investment in these products. As a result, Axcelis  decided  to cease future product development in  RTP
to focus  on profitable growth within  the  company’s core ion implant and  dry  strip  businesses.

Axcelis has initiatives underway to seek  ways to utilize  our existing products  in alternative markets
such as solar and LED (Light-Emitting Diode). We are also  evaluating  technologies and products  that
might enhance and extend our existing  product  portfolio.

Aftermarket Support and Services

We  offer our customers extensive aftermarket service and support  throughout the  lifecycle  of  the

equipment we manufacture. We believe  that  approximately  3,000 of our products are in  use in
30 countries worldwide. The service and support that  we provide  include  spare parts,  equipment
upgrades, and maintenance services. We provide  service  out  of  32 field  offices to customers located  in
30 countries. Revenue generated through  our service  and  support business  represented about 51.7%,
73.8%, and 57.1% of revenue in 2010, 2009, and 2008, respectively.

We  have 412 staff, including sales and marketing personnel,  field service engineers, and spare parts

and applications engineers, as well as  employees located  at our  manufacturing facilities who  work with
our  customers to provide customer training and  documentation, product,  process and applications
support.

Most of our customers maintain spare parts  inventories for our  machines.  In  addition to our

web-based spare parts management and  replenishment tracking  program, we offer a number of
Business-to-Business options to support our  customers’  parts  management requirements.  AMI  (Axcelis
Managed Inventory) provides the customer  with full  spares  support through which  Axcelis takes
responsibility for the complete supply  chain. The expansion of  these services provides ease of use
alternatives that help us reduce order  fulfillment  costs and improve cycle time, resulting in an expanded
customer base for this service offering.  See Note 2 to our Consolidated Financial Statements contained
in Item 15 of this Form 10-K for a discussion of revenue classifications  from  our  aftermarket business.

Sales and Marketing

We  primarily sell our equipment and  services through our direct sales  force. We  have 14 sales
offices in 7 countries. Aftermarket service  and  support  is also  offered  at all of these offices. In the
United States, we conduct sales and marketing activities from seven locations. Outside of  the
United States, our sales offices are located in Taiwan,  South  Korea, China, Germany, Singapore and
Italy. In addition, isolated sales are made  in smaller markets through distributors and manufacturing
representatives.

5

In Japan, SEN Corporation, or ‘‘SEN’’, has a non-exclusive license to use  certain patented and

unpatented technology associated with  legacy products owned by the Company. This  license does not
restrict our ability to sell any of our products in Japan. See Note  16 to our  Consolidated  Financial
Statements contained in Item 15 of this  Annual  Report on  Form 10-K for further information
regarding SEN. We support our products  in Japan through a representative agreement  with Applied
Materials, Inc., which provides aftermarket services  and  support services  for  our  products.

International revenue, including export sales from  our  U.S.  manufacturing facilities to foreign

customers, sales by foreign subsidiaries and branches, and royalties, accounted for  75.8% of total
revenue in 2010, 62.8% in 2009, and 64.7% in 2008. Substantially  all of our sales  are denominated in
U.S. dollars. See Note 17 to our Consolidated  Financial Statements contained in Item  15 of this
Form 10-K for a breakdown of our revenue and long-lived assets in  the United States,  Europe
and Asia.

Customers

In 2010, the top 20 semiconductor manufacturers accounted for  approximately 78.9%  of  total

semiconductor industry capital spending,  up from 72.5%  in 2009.  These manufacturers are  from the
four  largest semiconductor manufacturing  regions in the world: the United States, Asia  Pacific  (Taiwan,
South Korea, Singapore, and China),  Japan  and Europe. The Company  serves  all  leading
semiconductor manufacturers. We believe that  more  than  4,000 of our products, including  products
shipped by our former Japanese joint venture prior  to  our divestiture of that company  in 2009, are  in
use worldwide.

Revenue from our ten largest customers  accounted  for 62.7%, 56.6%, and 51.5% of  revenue in
2010, 2009, and 2008, respectively. We  expect that sales of  our products to relatively few customers will
continue to account for a high percentage of revenue for the foreseeable future.  In 2010, one customer
accounted for 18.6% of revenue. In 2009, no customer  accounted for  more than  10% of revenue.

Research and Development

Our industry continues to experience rapid technological change, requiring us to frequently
introduce new products and enhancements.  Our ability to remain competitive in this  market  will
depend  in part upon our ability to develop new and enhanced systems and to introduce these systems
at competitive prices on a timely and cost effective  basis.

We  devote a significant portion of our  personnel and financial  resources to  research  and
development programs and seek to maintain close relationships with  our  customers to remain
responsive to their product needs. We  have also sought  to  reduce the development cycle for  new
products through a collaborative process  whereby our engineering, manufacturing  and marketing
personnel work closely together with  one  another and with our customers at  an earlier stage in the
process. We also use 3D, computer-aided design, finite element  analysis and other computer-based
modeling methods to test new designs.

Our expenditures for research and development were $39.5 million, $32.7 million and $63.3 million

in 2010, 2009, and  2008, respectively, or 14.4%, 24.6%  and  25.3%  of  revenue,  respectively. We  expect
that research and development expenditures  will continue to represent a substantial investment in
future years.

Manufacturing

We  manufacture products at our 417,000 sq. ft.  ISO 9000:2008, ISO 14001:2004 certified plant in

Beverly, Massachusetts. Our facility employs best  in class  manufacturing techniques  including lean
manufacturing, six sigma controls and  advanced inventory management, purchasing and  quality systems.

6

Our clean manufacturing process uses  class 1000/10,000 space to facilitate  most of our manufacturing
requirements.

Products are designed to be assembled and  tested in a modular fashion which facilitates  our

industry recognized ship-from-cell process. Specially developed test stands, software  and tooling provide
the framework for this accelerated delivery  process. Customers that  choose ship-from-cell substantially
improve their delivery times while receiving  the same high  level  of  quality provided by more traditional
longer cycle integration techniques. Product margins and inventory turns also improve as a result  of
shorter factory cycle times and increased  labor productivity.

Installation of our equipment is provided by  factory  and  field teams. The process includes placing
and leveling the equipment at its installation site, connecting it  to  sources  of gas, water  and electricity
and recalibrating it to specifications that  had previously been  met  during  factory testing.

Our supply chain team is globally focused and is  located  in Beverly  and Singapore. Customized
and commercially available software solutions drive our  planning, purchasing and  inventory tracking
process. Material is supplied from a number  of sources that  provide OEM  or product  built to our
detailed specifications.

Core manufacturing competency is built around system assembly and test  which remains an in

house capability due to the high degree  of expertise and intellectual  property  associated with the
process and design. Non-core work is  sourced  to  one  of several  global partners and  includes items such
as power distribution, vacuum systems, wafer  handling and commodity level components.  We
continuously pursue outsourcing opportunities  where the  economics are justified,  with a goal of
enabling factory capacity, quality and margin improvement.

Beverly, Massachusetts is also the location of our Advanced Technology Center. This  center houses

a process development laboratory with 12,500 sq. ft.  of  class  10/100/1000 clean  room  for product
demonstrations and process development and a 34,000 sq. ft. customer training  center. The Advanced
Technology Center provides infrastructure  and process capabilities that allow customers to test their
unique  process steps on our product  under conditions that substantially  replicate  the customers’
production environment. This facility  also  provides significant  capability for our research and
development efforts.

Competition

The semiconductor wafer fabrication equipment market is highly  competitive  and is characterized
by a small number of medium to large size participants. We compete  in two principal product markets
in both the front-end and back-end of  the semiconductor  wafer fabrication process: ion implantation
and dry strip. We believe that preexisting relationships have a significant influence on  a customer’s
choice of equipment supplier. Other significant  competitive  factors in the semiconductor equipment
market include price, cost of ownership,  equipment performance, customer  support, breadth of  product
line, distribution and financial viability.

Ion Implantation.

In ion implantation, we compete against Varian Semiconductor Equipment

Associates, Inc., SEN, Nissin Electric Co., Ltd.  and AIBT.

Dry  Strip. Our principal competitors in the dry strip  product market are PSK, Inc., Mattson

Technology Inc. and Novellus Systems, Inc.

7

Intellectual Property

We  rely on patent, copyright, trademark and trade  secret  protection, as  well as contractual
restrictions, in the United States and in  other countries  to  protect our  proprietary  rights in  our
products and our business. As of January 1,  2011, we  had 248  patents issued in the United States and
245 patents granted in other countries, as  well as  528 patent applications (83 in the  United States and
445 in other countries) on file with various  patent  agencies worldwide.  Patents  are generally in  effect
for up to 20 years from the filing of the application.

We  intend to file additional patent applications and grow  our  intellectual  property  portfolio  as

appropriate. Although patents are important to our  business,  we do not believe  that  we are
substantially dependent on any single patent  or any  group of patents.

We  have trademarks, both registered  and  unregistered, that  are  maintained to provide customer

recognition for our products in the marketplace.

From time to time, we enter into license agreements with  third parties under which we  obtain  or

grant rights to patented or proprietary  technology. Except for our license  agreement with SEN
(described above under ‘‘Sale of Investment’’), we  do not  believe that any of our licenses are currently
material to us.

We  can give no assurance that we, our licensors, licensees,  customers or suppliers will  not  be
subject to claims of patent infringement or claims to invalidate our patents, or  that  any such claims will
not be successful, requiring us to pay substantial damages or delete  certain features from  our  products
or both.

Backlog

As of December 31, 2010, our systems backlog (excluding deferred systems revenue) was
$51.7 million, as compared to $10.8 million as of  December 31,  2009. Systems backlog including
deferred systems revenue was $68.0 million and $16.5 million as of  December 31,  2010 and  2009,
respectively. The increase in backlog is indicative of the overall trend  toward  recovery in the
semiconductor equipment market. We  believe it is meaningful to investors to include deferred systems
revenue as part of our backlog. Deferred  systems revenue represents revenue  that  will  be  recognized in
future periods based on prior shipments.  Our  policy  is to include in  backlog only those system orders
for which we have accepted purchase orders and typically are due  to  ship  within six months. Backlog
does not include orders received for our service business (spare parts,  consumables  and service
contracts) due to the turn rate associated  with that business. Generally, orders  for services or  parts
received during the quarter are performed or shipped within the  same quarter. All orders are  subject to
cancellations or rescheduling by customers with  limited  or no  penalties. Due  to  possible changes  in
system delivery schedules, cancellations  of orders, and delays in systems  shipments, our  backlog at any
particular date is not necessarily indicative  of  our actual sales for any succeeding period.  In  addition,
our  backlog at the beginning of a quarter typically does  not  include all orders required  to  achieve  our
sales objectives for that quarter and is  not a reliable indicator of  our future sales.

Employees

As of December 31, 2010, we had 1,018  employees and 113 temporary  staff worldwide, of which

862 work in North America, 201 in Asia  and  68 in Europe. We consider  our relationship with our
employees to be good. Our employees  are not represented by a  labor union and  are not subject to a
collective bargaining agreement. Some  of our European locations have formed work councils, which
have certain information and discussion rights under  applicable law.

8

Environmental

We  are subject to environmental laws and regulations in the  countries in which we operate that

regulate, among other things: air emissions; water discharges; and the generation, use, storage,
transportation, handling and disposal of  solid  and hazardous  wastes produced  by  our  manufacturing,
research and development and sales activities. As with other companies engaged in  like businesses,  the
nature of our operations exposes us to  the risk of environmental liabilities, claims, penalties and orders.
We  believe, however, that our operations are  in substantial compliance with applicable  environmental
laws and regulations and that there are no pending environmental  matters  that  would have a  material
impact on our business. We are ISO-14001 certified at  our Beverly, MA  facility.

Executive Officers of the Registrant

Mary G. Puma, 53, has been our President and Chief Executive Officer since January 2002  and

Chairman since 2005. From May 2000 until January 2002, Ms. Puma was our  President and  Chief
Operating Officer, prior to which she served as a Vice President of  Axcelis from February 1999. In
1998, she became General Manager and  Vice President of the Implant Systems Division of Eaton
Corporation, a global diversified industrial manufacturer. In  May 1996,  she joined Eaton as  General
Manager of the Commercial Controls  Division. Prior to joining Eaton, Ms. Puma spent 15 years in
various marketing and general management positions for General Electric Company. Ms. Puma  is a
director of Nordson Corporation, North Shore Medical Center and  Semiconductor Equipment and
Materials International (SEMI).

Jay Zager, 61, became our Executive Vice  President  and Chief  Financial Officer in January  2011.

Prior to joining Axcelis, from 2007 until 2010, Mr. Zager was Executive Vice  President  and Chief
Financial Officer at 3Com Corporation,  a  global enterprise networking solutions provider  acquired  by
Hewlett Packard. From February 2005  until  June 2007, Mr. Zager was Executive Vice President and
Chief Financial Officer at Gerber Scientific,  Inc., a supplier  of  automated manufacturing  systems. Prior
to joining Gerber,  Mr. Zager was Senior  Vice President and Chief Financial  Officer of  Helix
Technology Corp., a semiconductor equipment manufacturer, from February 2002.

Stephen G. Bassett, 63, is our Executive Vice President, Finance, a position  he has held since
May 2005. Until January 2011, Mr. Bassett  was our Chief  Financial  Officer from  April 2004.  He  was
also Senior Vice President, Finance from 2004  until May 2005. Prior to that, Mr. Bassett had  served as
interim Chief Financial Officer for Axcelis beginning in June 2003.  From 1999 to 2002, Mr. Bassett
served as Chief Financial Officer of Ezenia! Inc., a  provider of real-time voice, video and data
collaboration solutions for corporate  networks and the Internet. From 1996  to  1999, Mr. Bassett
worked as an independent financial consultant. From  1981 until 1996,  Mr.  Bassett served as an audit
partner at Ernst & Young LLP, where  he managed auditing services for a variety of organizations,
ranging from multinational Fortune 500 companies to emerging businesses.

Kevin J. Brewer, 52, is our Executive Vice President, Manufacturing  Operations, a  position  he has

held since November 2008, prior to which he had been Vice  President  of Manufacturing Operations
since October 2002 and Director of Operations from  1999 to 2002. Prior to  joining Axcelis  in 1999,
Mr. Brewer was Director of Operations, Business Jets at  Raytheon Aircraft Company, a  leading
manufacturer of business and special  mission aircraft owned by  Raytheon Company, a  manufacturer of
defense, government and commercial electronics,  as well  as aircraft.  Prior to that, Mr. Brewer held
various management positions in operations and strategic planning in Raytheon  Company’s Electronic
Systems and Missile Systems groups.

Lynnette C. Fallon, 51, has been our General Counsel and corporate Secretary since 2001 and
Executive Vice President, Human Resources/Legal since May 2005. Prior  to  that,  Ms. Fallon  was  Senior
Vice President HR/Legal since 2002, and  Senior Vice President since  2001. Before  joining Axcelis,

9

Ms. Fallon was a partner in the Boston  law firm of Palmer & Dodge LLP  since 1992, where she was
head of the Business Law Department from 1997 to 2001.

Matthew P. Flynn, 54, is our Executive Vice President, Global  Customer Operations, a position he

has held since May 2005, prior to which he  was Vice President Global  Customer Operations since
October 2002. Before then, Mr. Flynn  was Director of Sales, Ion Implant and  RTP  systems. Prior to
joining Axcelis in 1996, Mr. Flynn held  executive and management roles  at Cherry Semiconductor,  an
integrated circuit manufacturer, and at Teledyne Inc.,  in its  microelectronics business.

William Bintz, 54, has been our Senior  Vice President, Marketing  since September 2007.  Mr.  Bintz

joined Axcelis in early 2006 as Director  of Marketing for curing and cleaning products  and shortly
thereafter became Vice President of Product Marketing  where he  expanded his responsibilities to
include implant products as well. Prior  to  joining Axcelis,  from 2002 Mr.  Bintz was Product Director
for Medium Current and High Energy Ion Implant System at Varian Semiconductor Equipment
Associates, Inc. Before that, he was General Manager of the Materials Delivery Products Group  at
MKS Instruments, beginning in 1999,  and General Manager of the Thermal Processing Systems
Division at Eaton Corporation (now  Axcelis) beginning in 1995.

Item 1A. Risk Factors.

Some of the matters discussed in this filing contain forward-looking statements regarding  future
events that are subject to risks and uncertainties.  From time to time, we may also  make  other  forward-
looking public statements, such as statements concerning  our expected future revenue or  earnings or
concerning the prospects for our markets or our product development, projected plans, performance,
order procurement as well as other estimates relating  to  future operations. Forward-looking statements
may be in reports filed under the Securities Exchange Act  of  1934, as amended (the ‘‘Exchange Act’’),
in registration statements filed under  the  Securities Act  of  1933, as amended (the ‘‘Securities Act’’), in
press releases or in informal statements  made with  the approval of an authorized  executive officer.  The
words or phrases ‘‘will likely result,’’  ‘‘are expected to,’’ ‘‘will continue,’’ ‘‘is anticipated,’’  ‘‘estimate,’’
‘‘project,’’ or similar expressions are intended  to  identify ‘‘forward-looking statements’’ within  the
meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act, as enacted by the
Private Securities Litigation Reform Act of 1995.

We  wish to caution you not to place undue reliance  on these forward-looking  statements.  These
statements speak only as of the date  on which they are made and represent management’s expectations
based on information available to them at that time. The factors  listed below, as  well as other factors
that we may or may not have currently  identified, could  affect our  financial or  other performance and
could cause our actual results for future  periods  to  differ materially from  opinions or statements
expressed with respect to future periods  or events  in any  current statement.

We  will not undertake, and specifically  decline,  any  obligation  to  publicly release revisions  to  these

forward-looking statements to reflect either circumstances after  the date of  the statements or the
occurrence of events that may cause us  to re-evaluate our forward-looking statements,  except as  may be
required by law.

Important factors that could cause our  actual results  to  differ  materially from those projected in
any forward-looking statements or that may otherwise be made by  us or on our behalf and that make
an investment in our securities risky  include,  but are  not limited to: the  cyclical nature  of  the
semiconductor industry, whether we can  keep  pace with rapid technological changes in  the
semiconductor manufacturing processes,  the highly  competitive nature of  the semiconductor  equipment
industry, and quarterly fluctuations in  operating results attributable to the timing  and amount of  orders
for our  products and services, as well as  the other risk factors, discussed below. If any of those  risk
factors actually occurs, our business,  financial  condition and results of operations could be seriously
harmed and the trading price of our  common  stock could  decline.

10

We may  be unable to obtain needed additional capital to  finance our operations.

Our capital requirements may vary widely from quarter to  quarter, depending on, among other

things, capital expenditures, fluctuations in our operating results,  financing  activities, acquisitions and
investments and inventory and receivables management. We believe that our  existing cash and  cash
equivalents will be sufficient to satisfy  our  anticipated cash requirements through the end  of 2011 and
beyond, but this, of course, depends on the accuracy of our assumptions about  levels of  sales and
expenses. A number of factors, including  those described in  these  ‘‘Risk Factors,’’ could prove  our
assumption wrong and cause us to require  additional capital from external sources. Depending  on
market conditions, future debt or equity  financings may  not  be  possible on attractive terms  or at  all.  In
addition, future debt or equity financings could be dilutive  to  the existing holders  of our  common stock.

If semiconductor manufacturers do not make  sufficient capital expenditures, our sales and  profitability will
be harmed.

Almost all of our new orders will depend upon demand  from semiconductor  manufacturers  who
build or  expand fabrication facilities. When the rate of construction or  expansion of fabrication  facilities
declines, demand for our systems will  decline, reducing our revenue. Revenue decline also hurts  our
profitability because our fixed cost structure  and  our continued  investments in engineering,  research
and development and marketing necessary to develop new products and  to maintain extensive customer
service and support capabilities limit our  ability to reduce expenses in proportion to declining  sales.

Our financial results may fluctuate significantly.

We  derive most of our revenue from the sale of a relatively  small number of expensive products to
a small  number of customers. The list prices  on these products range from  $0.2 million to $5.0 million.
At our current sales level, each sale,  or  failure  to  make  a sale,  has a material effect on us in a
particular quarter. In a given quarter, a number  of factors can adversely  affect our revenue  and results,
including changes in our product mix,  increased fixed expenses per unit due to reductions in  the
number of products manufactured, and  higher fixed costs due to increased  levels of  research  and
development and expansion of our worldwide sales and marketing organization. Our financial results
also fluctuate based on gross profit realized on  sales. A variety of factors  may cause  gross profit as a
percentage of revenue to vary, including the mix and average  selling prices  of  products sold,  costs to
manufacture and customize systems and  warranty costs.  New product  introductions may also  affect our
gross  margins. Fluctuations in our results  may  have an adverse effect on the  price of our common
stock.

Our financial results may fall short of anticipated  levels; forecasting revenue and profitability is  complex  and
may be inaccurate.

Management may from time to time  provide financial forecasts. These forecasts are  based on
assumptions believed to be reasonable when made of shipment timing  and contract terms.  However, in
some cases, the final customer terms may not have been agreed  and documented  at the time the
forecast is made, so the level of revenue  recognizable in a particular quarter may vary from the
forecast. Our lengthy sales cycle, coupled  with customers’ competing capital budget  considerations,
make the timing of customer orders uneven and difficult to predict. In addition, our  backlog at the
beginning of a quarter typically does not  include all orders required to achieve our sales objectives for
that quarter and is not a reliable indicator  of our future  sales.  As a result, our  revenue and operating
results for a quarter depend on our shipping orders as  scheduled during that quarter, receiving
customer acceptance of shipped products  during the quarter, and obtaining new  orders  for products to
be shipped in that same quarter. Any delay in, or cancellation of, scheduled shipments and  customer
acceptances or in shipments from new orders could materially and adversely  affect our financial results.

11

Accounting rules addressing revenue  recognition  have added additional  complexity in  forecasting
quarterly revenue  and profitability. Orders  for  our  products usually contain multiple delivery elements
that result in revenue deferral under generally accepted accounting principles. Due to the foregoing
factors, investors should understand that  our actual financial results  for  a quarter may vary significantly
from our forecasts of financial performance for that quarter. Failure to meet  forecast  financial
performance may have an adverse effect  on the price of our common stock.

The semiconductor industry is highly cyclical and  we expect that demand for  our  products will regularly
increase and decrease, making it difficult to manage the  business  and potentially causing harm  to our sales
and profitability.

The semiconductor business is highly  cyclical, experiencing upturns when the demand for our
products is high and downturns when our customers are  not  investing in new or  expanded  fabrication
facilities. From time to time, inventory buildups  in the semiconductor industry, resulting  in part  from
periodic downturns, produce an oversupply  of semiconductors. This will cause semiconductor
manufacturers to revise capital spending  plans, resulting in reduced demand for capital equipment such
as our products. If an oversupply is not  reduced by increasing demand from  the various electronics
industries that use semiconductors, which we  cannot accurately  predict, our  sales  and profitability  will
be harmed. Our revenue can vary significantly from  one  point in  the cycle  to  another,  making it
difficult to manage the business, both when revenue is increasing and when it  is decreasing. In addition,
a substantial portion of our operating expenses are fixed and do not fluctuate with changes in  volume.
Significant decreases in revenue can  therefore  have a disproportionate  effect  on profitability.

If we fail to develop and introduce reliable new or  enhanced products and services that meet the  needs  of
semiconductor manufacturers, our results will suffer.

Rapid  technological changes in semiconductor manufacturing processes require  us  to  respond
quickly to changing customer requirements. Our future success will depend in part upon  our  ability  to
develop, manufacture and successfully  introduce new systems and product  lines with improved
capabilities and to continue to enhance existing products. This will  depend upon a variety of factors,
including new product selection, timely  and  efficient completion of product  design and development
and of manufacturing and assembly processes, product performance in the field and effective sales and
marketing. In particular:

• We must develop the technical specifications of  competitive new systems, or enhancements to
our  existing systems, and manufacture  and  ship these systems  or  enhancements in  volume in  a
timely manner.

• We will need to accurately predict the  schedule  on which our customers  will be ready to

transition to new products, in order to accurately forecast demand  for new products  while
managing the transition from older products.

• We will need to effectively manage  product reliability or quality problems that often exist  with

new systems, in order to avoid reduced orders, higher manufacturing costs, delays  in acceptance
and payment and additional service and warranty expenses.

• Our new products must be accepted in the marketplace.

Our failure to meet any of these requirements will  have a material  adverse effect  on our operating

results and profitability.

12

If we fail to compete successfully in the  highly competitive  semiconductor  equipment industry,  our  sales and
profitability will decline.

The market for semiconductor manufacturing equipment  is highly  competitive and includes
companies with substantially greater financial,  engineering, manufacturing, marketing and customer
service and support resources than we have that may be better positioned to compete successfully in
the industry. In addition, there are smaller,  emerging semiconductor equipment companies  that  provide
innovative systems with technology that may have  performance advantages over  our  systems. We expect
our  competitors to continue to improve  the design and performance of their existing  products and
processes and to introduce new products and processes with  improved price  and performance
characteristics. If we are unable to improve or introduce competing  products when demanded by the
markets, our business will be harmed.  In  addition,  if  competitors enter into strategic relationships with
leading semiconductor manufacturers  covering products similar to those sold or being developed by us,
our  ability to sell products to those manufacturers may be adversely  affected. Finally, if we must lower
prices to remain competitive without commensurate  cost of  goods savings, our  gross margins  and
profitability will be adversely affected.

We have  been dependent on sales to a limited  number of  large customers; the loss  of any  of  these customers or
any reduction in orders from them could  materially  affect our sales.

Historically, we have sold a significant portion  of our products and services to a  limited number  of

fabricators of semiconductor products. For example, in 2010,  our top ten customers accounted for
62.7% of our net sales. None of our  customers has entered into a long-term agreement requiring it  to
purchase our products. Although the composition of the group comprising our largest customers has
varied from year to year, the loss of a significant  customer or  any  reduction or delays in orders from
any significant customer could adversely affect us. The ongoing consolidation of semiconductor
manufacturers may also increase the  harmful  effect of losing  one or more significant customers.

Axcelis is  subject to the risks of operating internationally and  we derive a substantial  portion of our  revenue
from  outside the United States, especially from Asia.

We  are substantially dependent on sales of our  products and services to customers outside the

United States. International sales, including  export sales from  our U.S. manufacturing facilities to
non-U.S.  customers and sales by our  non-U.S. subsidiaries and branches,  accounted for 75.8% of  total
revenue in 2010, in comparison to 62.8%  in 2009  and  64.7% in 2008.  System shipments to Asian
customers represented 68% of total shipment  dollars in 2010 in comparison to 76% of  total  shipment
dollars in 2009. We anticipate that international sales will continue to account for  a significant portion
of our revenue. Because of our dependence upon international sales, our results  and prospects may  be
adversely affected by a number of factors, including:

• unexpected changes in laws or regulations resulting in  more burdensome governmental controls,

tariffs,  restrictions, embargoes or export license  requirements;

• difficulties in obtaining required export licenses;

• volatility in currency exchange rates;

• political and economic instability, particularly  in Asia;

• difficulties in accounts receivable collections;

• extended payment terms beyond those  customarily offered in the  United States;

• difficulties in managing suppliers, service  providers  or representatives outside the  United States;

13

• difficulties in staffing and managing foreign  subsidiary and branch  operations; and

• potentially adverse tax consequences.

We may  not be able to maintain and expand our business  if we  are  not  able to hire,  retain and  integrate
qualified personnel.

Our business depends on our ability to attract and retain qualified, experienced  employees. There

is substantial competition for experienced engineering, technical, financial, sales and marketing
personnel in our industry. In particular, we must  attract and retain  highly skilled design and  process
engineers. Competition for such personnel is  intense, particularly in the  Boston metropolitan area,  as
well as in other locations around the  world. If we  are unable to retain  our  existing key personnel, or
attract and retain additional qualified personnel, we may from  time to time experience levels  of  staffing
inadequate to develop, manufacture  and market our products and perform  services for  our customers.
As a result, our growth could be limited or  we could fail to meet our delivery  commitments or
experience deterioration in service levels or decreased customer satisfaction, all of  which could
adversely affect our financial results.

Our dependence upon a limited number  of  suppliers for  many components and sub-assemblies  could result in
increased costs or delays in the manufacture and  sale  of our  products.

We  rely to a substantial extent on outside  vendors  to  manufacture many of the  components and
sub-assemblies of our products. We obtain many of these components and  sub-assemblies from  either a
sole source or a limited group of suppliers. Accordingly, we may be unable  to  obtain  an adequate
supply of  required components on a  timely basis,  on price  and  other terms acceptable to us, or at all.

In addition, we often quote prices to  our  customers and accept customer orders for our products

before purchasing components and sub-assemblies  from our suppliers.  If our suppliers increase the cost
of components or sub-assemblies, we  may  not  have alternative sources of supply and  may not be able
to raise the price of our products to  cover  all  or part  of the increased cost  of  components.

The manufacture of some of these components and sub-assemblies is an extremely complex

process and requires long lead times.  As  a result, we have in the past and may in  the future  experience
delays or shortages. If we are unable to obtain adequate  and  timely  deliveries of our required
components or sub-assemblies, we may  have to seek alternative sources of supply or manufacture these
components internally. This could delay  our ability to manufacture or to ship our systems  on a timely
basis, causing us to lose sales, incur additional costs, delay new product  introductions  and suffer  harm
to our reputation.

Our international operations involve currency risk.

Substantially all of our sales are billed  in U.S. dollars, thereby reducing the impact of  fluctuations
in foreign exchange rates on our results. Operating margins  of  certain foreign operations can  fluctuate
with changes in foreign exchange rates  to the extent  revenue is billed in U.S. dollars  and operating
expenses are incurred in the local functional currency. During the  year ended December  31, 2010,
approximately 24% of our revenue was derived from  foreign operations with  this inherent risk.  In
addition, at December 31, 2010, our operations  outside of the  United States accounted for
approximately 34% of our total assets,  the majority of which was denominated  in currencies other than
the U.S.  dollar.

Our stock price has been volatile and you could lose the value of your investment.

Our stock price has been volatile and has  fluctuated  significantly to date.  The trading price  of  our
stock is likely to continue to be highly volatile and subject  to  wide fluctuations. Your investment  in our

14

stock could lose value. Some of the factors that could significantly  affect  the market  price of our stock
include:

• actual or anticipated variations in results;

• analyst  reports or recommendations;

• changes in interest rates; and

• other events and factors, many of which  are beyond our control.

The stock market in general has experienced extreme  price  fluctuations.

Our proprietary technology may be vulnerable  to efforts by competitors to challenge or design  around,
potentially reducing our market share.

We  rely on a combination of patents, copyrights, trademark and trade  secret laws, non-disclosure
agreements and other intellectual property protection methods to protect our proprietary technology.
Despite our efforts to protect our intellectual  property, our competitors may be able to legitimately
ascertain the non-patented proprietary technology embedded in our  systems. If this occurs, we may  not
be able to prevent their use of this technology. Our  means of protecting  our  proprietary rights may not
be adequate and our patents may not  be  sufficiently broad to prevent others  from using technology that
is similar to or the same as our technology. In addition, patents issued to us have  been, or might  be
challenged, and might be invalidated or  circumvented  and any rights granted under  our patents  may
not provide adequate protection to us. Our competitors may  independently develop similar technology,
duplicate features  of our products or  design  around patents that may be issued  to  us. As a  result of
these threats to our proprietary technology, we  may have to resort to costly litigation to enforce or
defend  our intellectual property rights.  Finally, all patents expire after  a  period  of  time (in the  U.S.,
patents expire 20 years from the date  of  filing of the  patent  application). Our market share could be
negatively impacted by the expiration  of  a  patent  which had created a barrier for our competitors.

Axcelis also has agreements with third parties for licensing of patented or proprietary  technology
with Axcelis as the licensor or the licensee. Termination  of license agreements could have an adverse
impact on our financial performance or  ability to ship products  with existing configurations.

We (or customers that we indemnify) might face intellectual property infringement claims or patent disputes
that may be costly to resolve and, if resolved against us,  could be very costly to  us and prevent  us from
making and selling our systems.

From time to time, claims and proceedings have  been or may  be  asserted  against us relative to
patent validity or infringement matters.  We typically  agree  to indemnify  our customers from  liability to
third parties for intellectual property  infringement arising from the use  of  our products in  their
intended manner. Therefore, we occasionally receive  notification from  customers who  believe that we
owe them indemnification or other obligations related to infringement claims made  against the
customers by third parties. Our involvement in any patent dispute or other intellectual property dispute
or action to  protect trade secrets, even if  the claims are  without  merit, could be very expensive  to
defend  and could divert the attention  of our management. Adverse  determinations in any litigation
could subject us to significant liabilities to third parties, require us  to  seek  costly  licenses from  third
parties and prevent us from manufacturing  and  selling our systems. In addition, infringement
indemnification clauses in system sale agreements  may require us to take other actions  or require us to
provide certain remedies to customers  who are exposed to indemnified liabilities.  Any  of  these
situations could have a material adverse effect  on our business results.

15

If operations were disrupted at Axcelis’ primary  manufacturing facility  it would  have  a negative impact on our
business.

We  have one primary manufacturing  facility, located  in Massachusetts. Its operations could be

subject to disruption for a variety of reasons, including, but not limited to natural  disasters, work
stoppages, operational facility constraints  and terrorism. Such disruption could cause delays in
shipments of products to our customers  and  could result in cancellation of orders or  loss of  customers,
which  could seriously harm our business.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

We  own one property and lease 49 properties,  of  which 14  are located in  the United  States  and
the remainder are located in Asia and  Europe, including offices in  Taiwan, Singapore, South Korea,
China, Malaysia, Italy, and Germany.

Our principal facilities are listed below:

Facility  Location

Principal Use

Beverly, Massachusetts Manufacturing, research and development, sales/marketing,
customer support, advanced process development, product
demonstration, customer-training center and  corporate
headquarters.

Square Footage
(Owned Leased)

417,000
(owned)

Rockville, Maryland

Research and development, marketing and customer
support.

22,000
(leased)

Although we are currently operating significantly  below normal capacity as a result of the

continuing downturn in the industry, we believe that there  is no material long-term, excess capacity  in
our  manufacturing facilities, although utilization is subject  to change  based on  customer demand.  We
believe that our manufacturing facilities  and equipment generally are well maintained, in good
operating condition, suitable for our  purposes, and  adequate  for our  present  operations.  Our Beverly,
Massachusetts facility is ISO 9001 and ISO 14001 certified and all other locations are ISO 9001
certified.

Item 3. Legal Proceedings.

The Company is not presently a party to any litigation that it  believes  might have a  material
adverse effect on its business operations.  The Company is, from time to time, a party  to  litigation  that
arises in  the normal course of its business operations.

Item 4. Submission of Matters to a Vote of  Security Holders.

None.

16

PART II

Item 5. Market for Registrant’s Common  Equity, Related  Stockholder Matters and Issuer Purchases

of Equity Securities.

Our common stock trades on the Nasdaq Global Select Market under the symbol ACLS. The
following table sets forth the high and  low sale prices  as reported on the Nasdaq Global Select Market
during each of the quarters for the two  most recent years. As of  March 14,  2011, we  had approximately
5,200 stockholders of record. We have not paid  any cash dividends in the  past five  years  and do  not
anticipate paying cash dividends in the  future.

Common Stock Price

High

Low

2009
First Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2010
First Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$0.70
$0.66
$1.29
$1.78

$1.86
$2.58
$1.96
$3.72

$0.17
$0.32
$0.32
$0.75

$1.41
$1.44
$1.34
$1.80

17

Item 6. Selected Financial Data.

The following selected consolidated statements  of operations  data for each of the three years
ended December 31, 2010, 2009, and  2008 and  the consolidated balance sheet data as of December 31,
2010 and 2009 have been derived from  the audited  consolidated  financial statements contained in
Item 15 of Part IV of this Form 10-K. The selected consolidated balance sheet data as  of December 31,
2008 and 2007, and the statement of operations data for the years ended  December 31, 2007 and 2006,
has been derived from the audited financial  statements  contained  in our Form  10-K filed  on March 31,
2009. The consolidated balance sheet  data as of December 31, 2006 has  been derived  from the audited
financial statements contained in our Form 10-K filed on  March 15, 2007.

The historical financial information set forth below may  not  be  indicative of our future

performance and should be read together  with ‘‘Management’s Discussion  and Analysis of  Financial
Condition and Results of Operations’’  and our historical consolidated financial statements and  notes to
those statements included in Item 7  of  Part II and Item 15  of  Part IV,  respectively, of this Form 10-K.

Consolidated statements of operations data:
Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross profit . . . . . . . . . . . . . . . . . . . . . . . . .
Equity income (loss) of SEN . . . . . . . . . . . . .
Income (loss) before Income taxes . . . . . . . . .
Net income (loss) . . . . . . . . . . . . . . . . . . . . .
Net income (loss) per share:
Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Shares used in computing basic and diluted

per  share amounts:

Years ended December 31,

2010

2009

2008

2007

2006

(In thousands, except per share amounts)

$275,212
85,838
—
(17,261)
(17,573)

$133,022
28,064
(3,238)
(76,603)
(77,468)

$ 250,214
62,615
(3,667)
(195,803)
(196,664)

$404,800
152,861
10,416
(11,808)
(11,398)

$461,717
191,514
19,266
42,783
40,770

$
$

(0.17) $
(0.17) $

(0.75) $
(0.75) $

(1.91) $
(1.91) $

(0.11) $
(0.11) $

0.40
0.40

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . .

104,522
104,522

103,586
103,586

102,739
102,739

101,891
101,891

101,058
101,361

Consolidated balance sheet data:
Cash and cash equivalents . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . .
Working capital
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term liabilities . . . . . . . . . . . . . . . . . . .
Stockholders’ equity . . . . . . . . . . . . . . . . . . .

$ 45,743
160,501
280,872
7,176
205,567

$ 45,020
163,849
250,603
4,447
216,399

$ 37,694
111,182
455,181
5,808
319,377

$ 83,877
284,679
669,929
89,920
486,006

$140,451
284,910
753,993
86,290
447,562

18

Item 7. Management’s Discussion and Analysis of Financial  Condition and  Results of  Operations.

Certain statements in ‘‘Management’s Discussion and Analysis  of Financial Condition  and Results
of Operations’’ are forward-looking statements  that involve risks  and uncertainties. Words  such as may,
will, should, would, anticipates, expects, intends, plans, believes, seeks, estimates  and similar  expressions
identify such forward-looking statements. The  forward-looking statements contained  herein  are based
on current expectations and entail various risks  and uncertainties that could cause actual results to
differ  materially from those expressed  in  such  forward-looking statements. Factors  that  might cause
such a difference include, among other things, those set forth under ‘‘Liquidity and Capital Resources’’
and ‘‘Risk Factors’’ and others discussed  elsewhere in this Form  10-K.  Readers are cautioned not to
place undue reliance on these forward-looking statements, which  reflect management’s analysis only as
of the date hereof. We assume no obligation to update  these forward-looking statements to reflect
actual results or changes in factors or assumptions affecting forward-looking statements,  except as  may
be required by law.

Overview

The semiconductor capital equipment industry is subject to significant  cyclical swings  in capital

spending by semiconductor manufacturers.  Capital spending is influenced  by  demand for
semiconductors and the products using them, the utilization rate and capacity of existing  semiconductor
manufacturing facilities and changes  in semiconductor  technology, all of  which are outside of our
control. As a result, our revenue and gross margins fluctuate from  year to  year and period to period.
We  typically become more efficient in  manufacturing  products as  they  mature. Our expense base is
largely fixed and does not vary significantly with changes  in volume. Therefore, we  experience
fluctuations in operating results and cash flows depending on  our revenue as  driven by the level of
capital expenditures by semiconductor manufacturers.

The sizable expense of building, upgrading or expanding a semiconductor fabrication facility  is

increasingly causing semiconductor companies to contract with foundries to  manufacture their
semiconductors. In addition, consolidation  and partnering within the semiconductor manufacturing
industry is increasing. We expect these trends  to  continue to reduce  the number  of  our  potential
customers. This growing concentration of Axcelis’  customers may increase pricing pressure as higher
percentages of our total revenue are tied  to  the buying decisions of  a particular customer or a small
number of customers. Axcelis’ net revenue from its ten largest customers accounted for 62.7% of total
revenue for the year ended December  31, 2010 compared  to,  56.6%, and 51.5% of revenue for  the
years ended December 31, 2009 and 2008,  respectively.

During  the last six months of 2007 and through  2009 challenging market conditions severely
limited our ability to increase sales and  market  share. During this period, adverse market  conditions
such as credit constriction, higher unemployment, lower corporate earnings, lower business investment
and lower consumer spending severely impacted  many  technology manufacturers and significantly
lowered the demand for our products.  During 2010, the  market  for  our products steadily improved. We
also estimate that we are gaining market share with  our  single wafer ion implant systems for  high
current and high energy applications (the Optima  HDx and Optima XEx),  as customers are showing a
higher  acceptance of our technology.  Our expense base is reduced from earlier periods due to cost
reduction initiatives implemented in 2009, 2008  and  2007.

Axcelis’ liquidity is affected by many factors. Some of these factors are based  on normal operations

of the business and others relate to the  uncertainties  of  global economies, including  the availability of
credit, and the state of the semiconductor  equipment  industry.  Although our cash requirements
fluctuate based on the timing and extent of these factors, based on  our current market, revenue  and
expense forecast we believe that our existing cash  and cash equivalents will be sufficient to satisfy our
anticipated cash requirements in the  short-term.

19

Operating results for the years presented are not necessarily indicative of the results  that  may be

expected for future interim periods or years as  a whole.

Critical Accounting Estimates

Management’s discussion and analysis  of our financial condition and results  of  operations  are
based upon Axcelis’ consolidated financial statements, which have been  prepared  in accordance with
accounting principles generally accepted  in  the United States. The  preparation of these financial
statements requires management to make  estimates and judgments that  affect the  reported amounts of
assets, liabilities, revenue and expenses,  and related  disclosure of contingent assets and  liabilities. On an
on-going basis, we evaluate our estimates,  including  those related to revenue  recognition, income taxes,
accounts receivable, inventory and warranty obligations. Management’s estimates are based  on historical
experience and on various other assumptions  that are believed to be reasonable under the
circumstances, the results of which form the basis  for making judgments  about  the carrying values of
assets and liabilities that are not readily  apparent from  other sources. Actual results  may differ from
these estimates under different assumptions  or conditions.

We  believe the following accounting policies are critical in the portrayal of our financial condition

and results of operations and require management’s  most significant judgments and  estimates in  the
preparation of our consolidated financial statements.

Revenue Recognition

Our revenue recognition policy involves significant  judgment by  management. As  described below,

we consider a broad array of facts and circumstances in determining when  to  recognize revenue,
including contractual future service obligations to the customer, the complexity of the  customer’s post
delivery acceptance provisions, payment history, customer creditworthiness and  the installation process.
In the future, if the post delivery acceptance provisions and  installation  process become more complex
or result in a materially lower rate of  acceptance, we may have to revise our revenue  recognition policy,
which  could delay the timing of revenue recognition.

Axcelis’ system sales transactions are made up of multiple elements, including the  system itself and

elements that are not delivered simultaneously with the system. These undelivered  elements might
include a combination of installation services,  extended warranty  and support and spare parts, all of
which  are covered by a single sales price.  The Company allocates revenue  among  the elements  using
the residual method, in which estimated fair market value is established for all elements  other  than  the
system itself and the remainder of the sales price is allocated  to  the  system.

The value of the undelivered elements includes  (a) the  greater of (i)  the fair value of the

installation or (ii) the portion of the  sales price that will not be received until  the installation is
completed (the ‘‘retention’’) plus (b)  the fair value of all other  undelivered elements.  The amount
allocated to installation is based upon the  fair value of the service performed, including labor, which is
based upon the estimated time to complete the installation at hourly rates, and material components.
The fair value of all other undelivered  elements  is based upon the  price charged when these  elements
are sold  separately. Product revenue  for products  which have  demonstrated market acceptance (legacy
products), is generally recognized upon  shipment provided title and risk of loss has passed to the
customer, evidence of an arrangement  exists, prices  are contractually  fixed  or determinable,  collection is
reasonably assured through historical  collection results and  regular credit evaluations, and there are  no
uncertainties regarding customer acceptance. Revenue from installation services is recognized  at the
time formal acceptance is received from the  customer or,  for certain  customers,  when both the  formal
acceptance and retention payment have been received. Revenue for other elements  is recognized at the
time products are shipped or the related  services are  performed.

20

We  generally recognize systems revenue  for  products which have demonstrated  market acceptance

(legacy products) at the time of shipment because the customer’s post-delivery acceptance provisions
and installation process have been established  to  be  routine, commercially inconsequential and
perfunctory. While some customers accept Axcelis’ standard  specifications, the majority  of  Axcelis’
systems are designed and tailored to  meet the  customer’s specifications, as outlined  in the contract
between the customer and Axcelis. To  ensure that the customer’s specifications are satisfied, many
customers request that new systems be  tested at Axcelis’ facilities prior to shipment, normally with  the
customer present, under conditions that substantially replicate the customer’s  production environment
and the customer’s criteria are confirmed  to  have been met. Customers of mature products generally
do not require pre-shipment testing. We believe the  risk of  failure to complete a  system installation is
remote. Should an installation not be  completed  successfully,  the contractual provisions  do not provide
for forfeiture, refund or other purchase  price concession beyond those prescribed by the provisions of
the Uniform Commercial Code applicable generally  to  such transactions.

For initial shipments of systems with new technologies or  in the small number  of  instances where

Axcelis is unsure of meeting the customer’s specifications or  obtaining customer  acceptance  upon
shipment of the system, Axcelis will defer the recognition of systems revenue  and related costs  until
written customer acceptance of the system is obtained. This deferral period is generally  within twelve
months of shipment.

Revenue related to maintenance and service contracts is  recognized ratably over  the duration of

the contracts, or based on parts usage,  where  appropriate.  Revenue related to service hours is
recognized when the services are performed.

Royalty revenue was primarily earned under the terms of our license agreement with SEN. Royalty

revenue was recorded at the time SEN notified the Company that royalties had been  earned.

Impairment of Intangibles and Long-Lived  Assets

We  record impairment losses on intangibles and long-lived assets  when events and  circumstances
indicate that these assets might not be recoverable.  Recoverability is measured  by  a comparison  of the
assets’ carrying amount to their expected  future undiscounted net cash flows. If such assets are
considered to be impaired, the impairment  is measured  based on the amount by which  the carrying
value exceeds its fair value. See Notes  2,6,7,8, and 9  to  our Consolidated Financial Statements
contained in Item 15 of this Annual Report on Form  10-K for  further information regarding
impairment of intangibles and long-lived  assets.

Future actual performance could be  materially different from our current forecasts, which could
impact future estimates of undiscounted cash flows and may result  in the impairment of  the carrying
amount of the long-lived assets in the future.  This could be caused by  strategic decisions made in
response to economic and competitive  conditions,  the impact of the economic environment on our
customer base, or a material adverse  change in  our relationships with significant  customers.
Accordingly, we will perform an impairment analysis  in the future when circumstances or events
warrant.

Accounts  Receivable—Allowance for Doubtful Accounts

We  record an allowance for doubtful  accounts for estimated  losses resulting  from the inability of

our  customers to make required payments.  If the financial condition of our customers were  to
deteriorate, resulting in an impairment  of their ability to make payments,  additional allowances may be
necessary.

21

Inventory—Allowance for Excess and Obsolescence

We  record an allowance for estimated excess and obsolete inventory.  The allowance  is determined

using management’s assumptions of materials  usage, based on estimates  of forecasted and  historical
demand and market conditions. If actual  market  conditions  become less favorable than those projected
by management, additional inventory write-downs may be required.

Although we make every effort to ensure the accuracy of our  forecasts or product  demand and

pricing assumptions, any significant unanticipated changes  in demand,  pricing, or  technical
developments would significantly impact the  value  of  our  inventory and our  reported operating results.
In the future, if we find that estimates  are  too optimistic  and determine that inventory needs to be
written down, the Company will recognize  such costs  in our  cost of revenue at the time of such
determination. Conversely, if we find our estimates are  too pessimistic and we subsequently  sell product
that has previously been written down, our gross margin in  that period will be favorably impacted.

Product Warranty

We  offer a one to three year product warranty,  the terms  and conditions of  which vary depending

upon the product sold. For all systems  sold,  we accrue a  liability  for the  estimated cost of standard
warranty at the time of system shipment and defer the  portion of systems revenue attributable to the
fair value of non-standard warranty. Costs for non-standard warranty are  expensed as  incurred. Factors
that affect our warranty liability include the number  of installed  units,  historical and  anticipated
product  failure rates, material usage  and service labor costs.  We periodically assess  the adequacy of our
recorded  liability and adjust the amount  as necessary.

22

Results of Operations

The following table sets forth our results of operations as a percentage of total revenue  for the

periods indicated:

Revenue:

Years Ended December 31,

2010

2009

2008

Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties, primarily from SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

88.2%
11.8
—

74.2%
25.5
0.3

77.6%
20.7
1.7

Total revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

100.0

100.0

100.0

Cost of revenue:

Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total cost of revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gross profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating expenses:

Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sales and marketing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
General and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of intangibles and long lived assets
. . . . . . . . . . . . . . . . . .
Amortization of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restructuring charges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Loss from operations: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other income (expense):

Gain on sale of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity loss of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other, net

Total other income (expense) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Loss before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

61.1
7.7

68.8

31.2

14.4
10.0
11.7
—
—
—
—

36.1

63.3
15.6

78.9

21.1

24.6
19.0
25.6
—
—
—
4.2

73.4

64.5
10.5

75.0

25.0

25.3
17.8
17.2
16.8
18.8
1.1
2.7

99.7

(4.9)

(52.3)

(74.7)

—
—
—
—
(1.5)

(1.5)

(6.4)
—

0.8
(2.4)
0.1
(1.3)
(2.6)

(5.4)

—
(1.5)
0.6
(2.6)
(0.1)

(3.6)

(57.7)
0.7

(78.3)
0.3

Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(6.4)% (58.4)% (78.6)%

Year ended December 31, 2010 in comparison to the year ended December 31, 2009

Revenue

Revenue increased significantly in 2010  compared to 2009 as  the  Company benefited  from
improving market conditions and increased capacity utilization at customers’ manufacturing facilities.
The Company expects this positive trend to continue into 2011.

Product

Product revenue, which includes systems sales, sales of spare  parts and product upgrades, was
$242.8 million or 88.2% of revenue in 2010, compared with $98.7  million,  or 74.2% of revenue in 2009.

23

The increase in product revenue in 2010 is attributable  to  the strengthening  of the semiconductor
market and a related increase in capital spending by semiconductor manufacturers. In addition, we also
believe we are gaining market share  with  our single wafer ion implant systems for  high current  and
high energy applications (the Optima  HDx and Optima  XEx), as customers are  showing a higher
acceptance of our technology.

Approximately 12.8% of systems revenue in 2010 was from  sales of  200mm products and  87.2%

was from sales of 300mm products, compared  with 25.0%  and 75.0%  for sales of 200mm products  and
300mm products in 2009, respectively.

A portion of our revenue from system sales is deferred until installation  and other services  related
to future deliverables are performed. The total amount of deferred revenue at  December 31,  2010 and
2009 was $16.3 million and $5.7 million, respectively. The increase was mainly due to the increase  in
systems sales in 2010.

Service

Service revenue, which includes the labor component of maintenance and service contracts  and
fees for service hours provided by on-site  service  personnel, was $32.4 million, or 11.8% of  revenue for
2010, compared with $33.9 million, or  25.5% of revenue, for  2009. Although  service  revenue should
increase with the expansion of the installed  base  of systems, it can  fluctuate from  period to period
based on capacity utilization at customers’ manufacturing facilities, which  affects the need for
equipment service. The slight decrease  during 2010  was primarily due  to  a decrease in  fabrication
utilization in the North American semiconductor industry.

Royalties

Royalties were previously earned under our prior license agreement with SEN. As  a result of  the

sale of our investment in SEN, SEN has  had no further  royalty obligations since March 30, 2009.
Royalty revenue was $0.4 million or  0.3% of revenue for  2009.

As an alternative to the line item revenue categories discussed above, management also uses

revenue categorizations which look at revenue  by product line (the most significant of which  is ion
implant) and by aftermarket, as described below.

Ion Implant

Included in total revenue of $275.2 million  in 2010 is  revenue  from  sales  of ion implantation

products and service of $232.4 million,  or 84.4% of total  revenue, compared with $110.9  million,  or
83.4%, of total revenue in 2009. The  dollar  increase was due to the factors discussed above for  product
revenue. Annual revenue from the sale of  ion implantation products and service typically averages from
70% to 80% of total revenue.

Aftermarket

The Company’s product revenue includes sales  of spare parts and product upgrades as  well as
complete systems. We refer to the business of selling spare parts and product upgrades, combined with
the sale of maintenance labor and service contracts and service hours, as the  ‘‘aftermarket’’ business.
Included in total revenue of $275.2 million  in 2010 is  revenue  from  our aftermarket  business  of
$142.2 million, compared to $98.2 million  for 2009. Aftermarket revenue generally increases with
expansion of the installed base of systems but can fluctuate from period to period  based on  capacity
utilization at customers’ manufacturing  facilities which affects the sale of  spare parts and  demand for
equipment service.

24

Gross  Profit

Product

Gross profit from product revenue was  30.8% for the twelve months ended December 31, 2010,

compared to 14.7% for the twelve months ended December 31, 2009. Approximately 3.3% of  the
16.1% increase resulted from a lower provision  for excess inventory.  The remaining  12.8% increase in
gross  profit from product revenue is  attributable to higher systems sales volume  and the  related
favorable absorption of fixed overhead costs which increased gross margins by 22.3%,  offset by a  9.5%
decrease in gross margin resulting from  an  unfavorable mix of parts and upgrade  revenue.

Service

Gross profit from service revenue was 34.3% for the  twelve  months ended December 31,  2010,
compared to 38.8% for the twelve months ended December 31, 2009. The decrease  in gross profit is
attributable to lower volumes.

Research and Development

Research and development expense was  $39.5 million in 2010,  an increase of $6.8 million,  or
20.8%, compared with $32.7 million  in  2009. The increase was  primarily  payroll costs due to increased
headcount ($3.1 million), increased professional fee expenses  ($2.4 million), increased project material
costs ($1.3 million), and increased asset  amortization and  depreciation  costs for assets  used  as
demonstration and/or test systems ($0.1  million).

Research and development expense was  attributable to the following activities for  2010: 53%  for

new product development, 31% for improvement of existing  products, and 16%  for product testing.

Sales and Marketing

Sales and marketing expense was $27.5  million  in 2010, an  increase of $2.3  million,  or 9.1%,
compared with $25.2 million in 2009  as  the Company  benefited from improved market conditions in
2010. The increase was driven primarily  by increased travel  costs  ($0.8 million), increased freight  costs
($0.8 million), increased supplies and  marketing costs ($0.4  million),  and  increased payroll costs
($0.3 million).

General and Administrative

General and administrative expense was  $32.1 million in 2010,  a decrease of $2.0 million,  or 5.9%
compared with $34.1 million in 2009.  The decrease was driven primarily by decreased  professional  fee
expenses ($4.6 million) primarily due  to  legal transaction  costs and  business outsourcing activities being
incurred in 2009 and a decrease in other miscellaneous costs ($0.4  million), offset  by  increased  payroll
and incentive compensation costs ($3.0 million).

Other Income (Expense)

Equity loss attributable to SEN was $3.2 million  for  the year ended December 31, 2009.  As a
result of the sale of the Company’s investment  in SEN, subsequent to March  30, 2009, the  Company no
longer records equity income or loss from SEN.

Interest income of $0.1 million for the  year  ended December 31, 2010, primarily relates  to  interest

earned on cash and cash equivalents. Interest income decreased by  $0.1 million from the  year ended
December 31, 2009, primarily due to lower average cash  balances  and lower interest rates.

25

We  had no interest expense for the year ended December  31, 2010. Our interest  expense was
$1.7 million for the year ended December  31, 2009. We have had no  borrowings since we paid in  full
our  convertible senior subordinated notes on  March 30,  2009.

For the year ended December 31, 2010 and 2009 the  Company incurred  $1.9 million  of foreign
exchange losses. Included in foreign exchange losses in  2010  are $0.3 million of foreign  exchange losses
relating to currency hedging activities. The primary reason for foreign  exchange losses in both years was
due to the weakening of the U.S dollar.

Income Taxes

We  incur income tax expense relating principally to operating results of foreign entities  in

jurisdictions, principally in Asia, where we earn taxable income. We have  significant net  operating loss
carryforwards in the United States and certain foreign jurisdictions, principally Europe, and,  as a result,
we do not currently pay significant income taxes in  those jurisdictions and we do  not  recognize the tax
benefit for such losses as discussed in  Note  18 to the consolidated  financial statements. Accordingly,
our  effective income tax rate is not meaningful.

In  2010,  the  Company  performed  an  evaluation  of  the  deferred  tax  assets  of  certain  of  our  foreign

subsidiaries for which the Company had  previously established a valuation allowance.  Based on  the
subsidiaries recent and expected ability to generate taxable income,  the Company  reduced  the
subsidiary’s corresponding valuation  allowance and recognized a tax benefit  of $1.3 million.

Year ended December 31, 2009 in comparison to the year ended December 31, 2008

Revenue

Revenue declined significantly in 2009 compared  to  2008 due  to  the continuing depressed

semiconductor equipment market.

Product

Product revenue, which includes systems sales, sales of spare  parts and product upgrades, was
$98.7 million or 74.2% of revenue in 2009, compared with $194.3  million,  or 77.6% of revenue in 2008.
The decline in product revenue in 2008 and  2009 was attributable to a weakening semiconductor
market and a related decrease in capital spending by  semiconductor manufacturers. In addition, a
decrease in 200mm manufacturing capacity (a portion of which relates  to the  overall  decline  in the
semiconductor capital equipment market) decreased revenue from system sales by $95.6 million
for 2009.

Approximately 25.0% of systems revenue in 2009  was from  sales of  200mm products and  75.0%

was from sales of 300mm products, compared with  41.0% and 59.0%  for sales of 200mm products  and
300mm products in 2008, respectively.

A portion of our revenue from system  sales  is deferred until installation  and other services  related
to future deliverables are performed. The  total  amount of deferred revenue at  December 31,  2009 and
2008 was $5.7 million and $14.4 million, respectively.  The  decline was mainly  due  to  the decrease in
overall systems revenue in 2009.

Service

Service revenue, which includes the labor  component  of maintenance and service contracts  and
fees for service hours provided by on-site service personnel, was $33.9 million, or 25.5% of  revenue for
2009, compared with $51.9 million, or  20.7% of  revenue, for  2008. The decline was due to a  continuing
decline  in overall market conditions and low capacity utilization at  customers’  manufacturing facilities.

26

Royalties

Royalty revenue was $0.4 million or  0.3% of revenue for  2009, compared  with $4.1 million, or
1.7% of revenue for 2008. Royalties were earned primarily under  our prior license agreement with
SEN. As a result of the sale of our investment  in SEN, SEN has had no further obligation  to  pay
royalties to us since March 30, 2009.

As an alternative to the line item revenue categories discussed above, management also uses

revenue categorizations which look at revenue  by product line (the most significant of which  is ion
implant) and by aftermarket, as described below.

Ion Implant

Included in total revenue of $133.0 million  in 2009 was  revenue from sales of  ion implantation
products and service of $110.9 million,  or 83.4% of total  revenue, compared with $204.9  million,  or
81.9%, of total revenue in 2008. The  decline was due to the  factors discussed above. Annual revenue
from the sale of ion implantation products  and service typically averages from 70%  to  80% of total
revenue.

Aftermarket

Included in total revenue of $133.0 million  in 2009 was  revenue from our  aftermarket business of

$98.2 million, compared to $143.0 million  for 2008. After hitting  bottom in the first quarter of  2009,
industry utilization increased each subsequent quarter  for the  remainder of the  year.  This resulted in
successive improvements in aftermarket revenue each quarter.

Gross  Profit

Product

Gross profit from product revenue was  14.7% for the twelve months ended December 31, 2009,

compared to 17.0% for the twelve months ended December 31, 2008. The decrease  resulted from
significantly lower systems sales volume  during the twelve months ended December 31, 2009, and  the
related under absorption of manufacturing  overhead which reduced  gross margins by 30.7%.  This was
offset by a 12.2% increase in gross margin resulting from the favorable impact  of an increased mix of
parts and upgrade revenue at higher  margins  and  16.2% attributable to a lower provision for excess
inventory.

Service

Gross profit from service revenue was 38.8% for the  twelve  months ended December 31,  2009,
compared to 49.2% for the twelve months ended December 31, 2008. The decrease  in gross profit was
attributable to significantly lower revenue.

Operating Expenses

In response to continuing weak market conditions in  2009 the Company took  several actions,

including reduction in headcount, to reduce operating  expenses. The aggregate  of  research  and
development, sales and marketing, and  general and administrative  expense reduction in 2009  compared
to 2008 was $58.9 million.

Research and Development

Research and development expense was  $32.7 million in 2009,  a  decrease of $30.6  million,  or
48.3%, compared with $63.3 million  in  2008. The decrease was primarily due  to  substantial completion

27

of Optima and Integra platform development  in 2008, which resulted in decreased payroll  costs
($12.4 million), decreased professional  fee expenses  ($3.2 million), decreased project material costs
($3.9 million), decreased development  asset  amortization and depreciation  costs for assets used  as
demonstration and/or test systems ($8.9  million)  and  decreased other miscellaneous expenses
($2.2 million).

Research and development expense was  attributable to the following activities for  2009: 49%  for

new product development, 35% for improvement of existing  products, and 16%  for product testing.

Sales and Marketing

Sales and marketing expense was $25.2  million  in 2009, a decrease of $19.4  million, or  43.5%,
compared with $44.6 million in 2008.  The decrease was driven primarily by decreased  payroll  costs
($9.5 million), decreased professional  services ($4.0 million), decreased  supplies and marketing  costs
($1.7 million), decreased travel costs  ($2.3 million), decreased freight  costs ($1.1 million) and  decreased
other miscellaneous costs ($0.8 million).

General and Administrative

General and administrative expense was  $34.1 million in 2009,  a decrease of $9.0 million,  or 20.8%

compared with $43.1 million in 2008.  The decrease was driven primarily by decreased  payroll  costs of
($4.5 million), decreased professional  fee expenses  ($2.2 million) decreased amortization costs
($1.1 million), and a decrease in other miscellaneous costs  ($1.2 million).

Impairment of Intangibles and Long-Lived Assets

The significant decline in our stock price  experienced at  the end of the  third  quarter  of  2008

continued through the end of the fourth  quarter and beyond, resulting  in a sustained market
capitalization well below book value.

During  2009 we continued to experience  events and circumstances which  indicated that a further

impairment of long-lived assets may have  occurred. The significant decline in our stock price continued
through 2009, and we continued to maintain a market capitalization significantly below book value.
However, the estimated future total market for  our products, which was significantly revised downward
in the fourth quarter of 2008, showed signs of modest  recovery  while still less than  historical levels.

Accordingly, as of December 31, 2009, we  performed  an analysis  comparing undiscounted cash

flows estimated to be generated by the long-lived assets to the carrying amounts of those assets. The
estimates of future operating results  and cash flows were  derived from  our updated  long-term financial
forecast, which represented the best estimate  that  we had at  the time.  This  forecast  relied primarily  on
market assumptions and market share  we expected to achieve. As of December 31, 2009,  our analysis
indicated that the carrying amounts for  long-lived  assets were expected  to  be  recovered. As such we did
not record an impairment charge for the  year ended December 31, 2009. As a result of our review of
the recoverability of intangibles and  long-lived assets, at  December 31,  2008, we  recorded an
impairment charge of $46.9 million consisting  of the entire net book value of  intangible  assets of
$8.3 million, certain other assets of $21.1 million, and property, plant and equipment of  $17.5 million.

Restructuring

During  the year ended December 31, 2009,  we implemented a reduction in force to further  reduce
costs to mitigate deteriorating industry fundamentals.  This  reduction in force resulted  in a total charge
to expense of approximately $6.1 million  related to separation and outplacement  costs for the year
ended December 31, 2009, offset by a reversal of $0.6 million of accrued  compensation  expense related
to terminated employees. A charge to expense of $5.5 million was recorded  in the year ended
December 31, 2009. See Note 10 to our Consolidated Financial Statements contained in  Item 15 of this
Annual Report on Form 10-K for further information regarding  our 2009 restructuring.

28

Changes in our restructuring liability during 2009, included in amounts reported  as other current

liabilities, are as follows:

Balance at December 31, 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Severance and related costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Severance

(in thousands)

$

746
6,084
(6,533)

Balance at December 31, 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

297

Other Income (Expense)

Equity loss attributable to SEN was $3.2 million  for  the year ended December 31, 2009.  This was
compared to equity loss attributable  to  SEN of $3.7  million  for the  year ended December  31, 2008. As
a result of the sale of our investment in  SEN,  subsequent to March 30,  2009, the Company no longer
has recorded equity income or loss from SEN.

Interest income of $0.2 million for the  year  ended December 31, 2009, primarily related to interest

earned on cash and cash equivalents. Interest income decreased by  $1.4 million from the  year ended
December 31, 2008, due primarily to lower average cash  balances.

Interest expense decreased by $5.1 million  for the  year ended December 31, 2009  compared to the

year ended December 31, 2008. The  decrease was due to the payment  in full of the  convertible senior
subordinated notes on March 30, 2009.

Income Taxes

We  incur income tax expense relating principally to operating results of foreign entities  in
jurisdictions, principally in Asia, where we earn taxable  income. During  2009 we  had significant net
operating loss carryforwards in the United States and certain foreign  jurisdictions, principally Europe,
and, as a result, we did not currently pay significant income taxes in those  jurisdictions and  we did  not
recognize the tax benefit for such losses as  discussed in Note 18 to the consolidated financial
statements. Accordingly, our effective  income tax rate was not meaningful.

Liquidity and Capital Resources

Capital expenditures were $1.4 million  and  $0.5 million  for  the years ended December 31, 2010

and 2009, respectively. We have no significant  capital projects planned for 2011 and  total  capital
expenditures for 2011 are projected to be less  than  $3.5 million. Future  capital expenditures  beyond
2011 will depend on a number of factors, including the timing and rate of expansion of our business
and our ability to generate cash to fund  them.

We  have outstanding standby letters of credit, bank  guarantees and surety bonds  in the amount of

$8.9 million to support certain operating  lease obligations, workers’  compensation  insurance, and
certain value added tax claims in Europe, of which $107,000 at  December  31, 2010 was  supported by
cash pledged as collateral. The pledged cash  is reflected as  long-term restricted cash on  the
consolidated balance sheet.

29

The following represents our commercial commitments  as  of  December  31, 2010 (in thousands):

Other Commercial Commitments

Total

2011

2012-2013

2014-2015

Thereafter

Amount of Commitment Expiration by Period

Surety bonds . . . . . . . . . . . . . . . .
Standby letters of credit . . . . . . . .
Statutory liability deposits . . . . . . .

$7,192
1,575
107

$2,742
1,575
—

$4,450
—
107

$8,874

$4,317

$4,557

$—
—
—

$—

$—
—
—

$—

The following represents our contractual  obligations as of  December  31, 2010  (in  thousands):

Contractual Obligations

Total

2011

2012-2013

2014-2015

Thereafter

Purchase order commitments . . .
Operating leases . . . . . . . . . . . .

$59,008
9,638

$59,008
2,955

$ — $ —
2,337

3,399

$68,646

$61,963

$3,399

$2,337

$ —
947

$947

Payments Due by Period

We  have no off-balance sheet arrangements  at December 31,  2010.

Our liquidity is affected by many factors. Some of  these relate specifically to the  operations  of  our

business, for example, the rate of sale of our  Optima and Integra  products, and others relate to the
uncertainties of global economies, including  the availability  of  credit, and the condition  of  the overall
semiconductor equipment industry.

We  have net operating loss and tax credit carryforwards the  tax  effect of which aggregate

$104.3 million at December 31, 2010.  These  carryforwards,  which expire principally between  2021 and
2030, are available to reduce future income tax liabilities  in the United States and  certain  foreign
jurisdictions.

In 2010, $5.9 million of cash was used to support operating activities which was $28 million  less
than in 2009. Cash used for operations in 2010  was predominately driven by the Company’s  net loss
from operations offset by non—cash  charges for  depreciation and amortization and stock based
compensation expense. Cash and cash  equivalents  at December 31,  2010 were  $45.7 million, compared
to $45.0 million at December 31, 2009.  Our 2011 plan includes improvement  in revenue,  operating
profit and cash flow.

On March 12, 2010, we amended our  existing revolving credit  facility with a bank. The amended

agreement provides for borrowings up to the lesser of $20 million  or specified percentages of the
amounts of qualifying accounts receivable  and inventory.  The  facility has certain financial covenants
requiring us to maintain minimum levels of operating  results and liquidity. On May 25,  2010, the
Company and its lender agreed to modify a financial  covenant in the  revolving credit facility regarding
maximum allowable quarterly losses.  Based on current  forecasts we believe we will be in  compliance
with the financial covenants throughout  the remaining term of the facility. Borrowings  made under the
facility will bear interest at the greater of 6% or  the bank’s prime rate plus 2%. At  no time during the
term of the agreement has the Company  borrowed against  the facility and $18.4 million was available
for borrowing as of December 31, 2010. The agreement will terminate on March 11, 2011. The
Company is currently in negotiations  with  several banks for a new  revolving credit facility on more
favorable terms than our current credit facility. The Company  expects the new credit facility  to  be  in
place during the second quarter of 2011. The Company has requested and has  been granted a  30 day
extension to its existing credit facility  until April 10, 2011.

We  believe that based on our current market, revenue and expense forecasts,  our existing cash  and

cash equivalents will be sufficient to  satisfy our anticipated cash requirements  in the short-term.  Our

30

2011 forecast reflects revenue and gross margins consistent with our  understanding of customer plans,
the market conditions currently forecasted by the industry, and capacity utilization at customers’
manufacturing facilities. Forecasted operating expense levels for 2011 reflect those in effect at the end
of 2010 adjusted for a moderate increase in research  and development  expense and a return to market
based employee compensation.

Recent  Accounting Pronouncements

In September 2009, the FASB issued a new accounting standard to provide guidance  on revenue

recognition criteria for multiple-element  arrangements. The new accounting standard  modifies the
criteria used to separate elements in  a  multiple-element arrangement  by introducing the concept of best
estimate of selling price, establishing  a  hierarchy of evidence  for determining selling  price (fair value),
requiring the use of relative selling price method  and  prohibiting the use  of  the residual method to
allocate arrangement consideration among units of accounting. The new accounting standard also
expands the disclosure requirements for  all  multiple element arrangements and is  effective
prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on
or after June 15, 2010 (January 1, 2011 for  a calendar year-end entity).  The  adoption of the new
accounting standard will not have a material impact on  the Company’s future operating results.

Item 7A. Quantitative and Qualitative Disclosures about Market  Risk.

Interest Rate Sensitivity

Axcelis’ exposure to market risk for changes  in interest rates relates primarily to our investment
portfolio, which consists entirely of cash-equivalents at December 31, 2010. The primary objective of
our  investment activities is to preserve  principal while maximizing yields without  significantly  increasing
risk. This is accomplished by investing  in  marketable  high investment grade securities and  limiting
exposure to any one issue or issuer. We  do not use  derivative  financial  instruments  in managing  our
investment portfolio and, due to the nature  of  our  investments, we  do not expect  our operating results
or cash flows to be affected to any significant degree by any change in market interest rates.

Foreign Currency Exchange Risk

Substantially all of our sales are billed  in U.S. dollars, thereby reducing the impact of  fluctuations
in foreign exchange rates on our results. Operating margins  of  certain foreign operations can  fluctuate
with changes in foreign exchange rates  to the extent  revenue are billed in U.S. dollars  and operating
expenses are incurred in the local functional currency. During the  years  ended December  31, 2010 and
2009, approximately 24% and 37% of our revenue were derived  from  foreign operations with  this
inherent risk. In addition, at both December 31,  2010 and 2009, our operations outside of the United
States accounted for approximately 34%  and  39% of our total  assets, respectively, the  majority of which
was denominated in currencies other  than the U.S.  dollar.

Item 8. Financial Statements and Supplementary Data.

Response to this Item is submitted as a separate section of  this report  immediately following

Item 15.

Item 9. Changes in and Disagreements with  Accountants on Accounting  and Financial Disclosure.

None.

31

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and  Procedures.

Our management, with the participation of our principal executive officer and principal financial

officer, has evaluated the effectiveness  of  our disclosure controls and procedures (as defined in
Rule 13a-15(e) under the Securities Exchange Act of  1934, as amended (the ‘‘Exchange Act’’)) as of
the end of the period covered by this  annual  report (the ‘‘Evaluation Date’’). Based on this evaluation,
our  principal executive officer and principal financial officer concluded  that,  as of the Evaluation Date,
these disclosure controls and procedures  are effective.

32

Internal Control over Financial Reporting

Management’s Annual Report on Internal Control  over Financial  Reporting

Management is responsible for establishing and maintaining adequate internal  control  over
financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Because of its
inherent limitations, internal control over financial reporting  may  not prevent or  detect  all
misstatements. A control system, no  matter  how well  designed  and operated, can provide only
reasonable assurance with respect to financial  statement preparation and  presentation. Projections of
any evaluation of effectiveness to future periods  are subject to the  risk that  controls may become
inadequate because of changes in conditions, or that the  degree  of compliance with  the policies or
procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial  reporting as of

December 31, 2010. In making this assessment, management used the  criteria set forth in the
Committee of Sponsoring Organizations  of  the Treadway Commission (COSO)  Internal  Control-
Integrated Framework.

Based on this assessment, management has concluded that, as of  December 31, 2010, our internal

control over financial reporting is effective based on those criteria.

The independent registered public accounting  firm  of Ernst & Young LLP, as  auditors of our
consolidated financial statements, has  issued an attestation report  on its  assessment  of  our  internal
control over financial reporting.

33

Report of Independent Registered Public  Accounting Firm

The Board of Directors and Stockholders of  Axcelis Technologies, Inc.

We  have audited Axcelis Technologies, Inc.’s  internal control  over financial reporting  as of

December 31, 2010, based on criteria established in Internal Control—Integrated Framework  issued by
the Committee of Sponsoring Organizations  of the Treadway Commission (the COSO criteria).  Axcelis
Technologies, Inc.’s management is responsible for  maintaining effective internal control over financial
reporting, and for its assessment of the  effectiveness  of  internal control  over financial reporting
included in the accompanying Management’s  Annual  Report on Internal  Control over  financial
reporting. Our responsibility is to express an  opinion on  the Company’s internal control over financial
reporting based on our audit.

We  conducted our audit in accordance with the standards of  the Public Company Accounting
Oversight Board (United States). Those  standards require that we  plan and perform the audit to obtain
reasonable assurance about whether  effective  internal control over financial reporting was maintained
in all material respects. Our audit included  obtaining an understanding  of internal control  over
financial reporting, assessing the risk that a  material weakness exists, testing and evaluating the design
and operating effectiveness of internal control based  on the assessed risk, and performing such other
procedures as we considered necessary in  the circumstances. We believe that our audit  provides a
reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide  reasonable

assurance regarding the reliability of  financial  reporting and the preparation  of  financial  statements  for
external  purposes in accordance with  generally accepted accounting  principles. A company’s internal
control over financial reporting includes those policies and procedures that (1)  pertain to the
maintenance of records that, in reasonable  detail, accurately and fairly reflect the  transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions  are
recorded  as necessary to permit preparation of financial statements in  accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made  only
in accordance with authorizations of management and directors of the company; and  (3) provide
reasonable assurance regarding prevention  or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that  could have a material effect on the financial statements.

Because of its inherent limitations, internal control over  financial  reporting may not prevent or

detect misstatements. Also, projections  of any evaluation  of  effectiveness to future periods are  subject
to the risk that controls may become inadequate  because of changes in conditions, or  that  the degree
of compliance with the policies or procedures may deteriorate.

In our opinion, Axcelis Technologies, Inc.  maintained, in all material respects,  effective internal

control over financial reporting as of  December 31, 2010,  based on the COSO criteria.

We  also have audited, in accordance with the standards of  the Public Company Accounting
Oversight Board (United States), the  consolidated balance sheets of Axcelis  Technologies,  Inc. as of
December 31, 2010 and 2009, and the related consolidated statements of operations, stockholders’
equity, and cash flows for each of the three years in the period ended December 31, 2010  of  Axcelis
Technologies, Inc. and our report dated March 14,  2011 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Boston, Massachusetts
March 14, 2011

34

Changes  in Internal Control over Financial Reporting

There was no change in our internal control over  financial  reporting (as defined in Rule  13a-15(f)

under the Exchange Act) identified in connection with the evaluation  of  our internal control  that
occurred during our fourth quarter that has  materially affected, or is  reasonably  likely to materially
affect, our internal control over financial  reporting.

Item 9B. Other Information.

None.

Item 10. Directors, Executive Officers  and  Corporate Governance.

PART III

A portion of the information required  by  Item 10 of Form  10-K is incorporated by reference from
the information responsive thereto contained in the  sections in Axcelis Proxy Statement for  the Annual
Meeting of Stockholders to be held April  26, 2011  (the ‘‘Proxy  Statement’’) captioned:

• ‘‘Proposal 1: Election of Directors,’’

• ‘‘Corporate Governance,’’ and

• ‘‘Other Matters—Section 16(a) Beneficial  Ownership  Reporting Compliance.’’

The remainder of such information is  set forth under the heading ‘‘Executive  Officers  of the

Registrant’’ at the end of Item 1 in Part  I of this report.

Item 11. Executive Compensation.

The information required by Item 11 of Form  10-K is incorporated by  reference from  the

information responsive thereto contained in the sections in the Proxy Statement captioned:

• ‘‘Executive Compensation,’’ and

• ‘‘Other Matters—Compensation Committee  Interlocks and Insider Participation.’’

Item 12. Security Ownership of Certain Beneficial Owners and Management  and Related Stockholder

Matters.

A portion of the information required  by  Item 12 of Form  10-K is incorporated by reference from

the information responsive thereto contained in the  sections in the Proxy Statement  captioned:

• ‘‘Share Ownership of 5% Stockholders,’’ and

• ‘‘Share Ownership of Directors and Executive  Officers.’’

The remainder of such information is  set forth below:

Equity Plan Reserves Disclosure

We  maintain two equity compensation plans, the 2000  Stock Plan and the Employee Stock

Purchase Plan. The number of shares  issuable upon exercise of outstanding  options  and unvested
restricted stock units granted to employees and non-employee directors,  as well as  the number  of

35

shares remaining available for future issuance, under our equity compensation  plans as of
December 31, 2010 are summarized  in  the following table:

Plan category

(A)
Number of shares
to be issued upon
exercise of
outstanding options,
warrents and rights(1)

(B)
Weighted-average
exercise price of
outstanding options,
warrants and rights

(C)
Number of
shares remaining
available for future
issuance under equity
compensation plans
(excluding shares reflected
in  column (A)(2)

Equity compensation plans approved

by stockholders . . . . . . . . . . . . . . . .

19,176,031

Equity compensation plans not

approved by stockholders . . . . . . . .

—

Total . . . . . . . . . . . . . . . . . . . . . . . . .

19,176,031

$3.70

—

$3.70

12,634,359

—

12,634,359

(1) Represents 18,947,509 shares issuable  on exercise of  outstanding options as of December 31,  2010,
plus 228,522 shares issuable on vesting of outstanding restricted stock units as of December 31,
2010 (some of which will be withheld to compensate  for  tax  withholding).

(2) Represents the total shares available  for issuance under  our 2000  Stock Plan and our Employee

Stock Purchase Plan, as of December  31, 2010, as follows:

(A) 9,890,721 shares were available for future  issuance  under the 2000 Stock Plan. Such amount
represents the total number of shares reserved for issuance under the 2000 Stock Plan
(33,173,367), less 418,880 outstanding shares  issued under the  plan as  restricted stock,
1,746,683 shares issued on vesting of outstanding restricted  stock  units, 1,941,052  shares issued
upon option exercises, and the outstanding options and unvested restricted  stock  units shown
in column (A), all as of December 31,  2010. This plan is  generally used for grants to
employees and directors and was approved by our stockholders at  our 2002 annual  meeting.

(B) 2,743,638 shares were available under  our  Employee Stock  Purchase Plan, which  represents

the total number of shares reserved for issuance under the  plan (7,500,000) less 4,756,362
shares issued through December 31, 2010.

Item 13. Certain Relationships and Related  Transactions and Director Independence.

The information required by Item 13 of Form  10-K is incorporated by  reference from  the

information responsive thereto contained in the sections in the Proxy Statement captioned:

• ‘‘Executive Compensation,’’

• ‘‘Corporate Governance—Board of Directors  Independence and Meetings,’’ and

• ‘‘Corporate Governance—Certain Relationships and Related Transactions.’’

Item 14. Principal Accounting Fees and Services

The information required by Item 14 of Form  10-K is incorporated by  reference from  the
information responsive thereto contained in the section captioned ‘‘Proposal 2:  Ratification of the
Appointment of our Independent Registered  Public Accounting Firm’’ in the  Proxy  Statement.

36

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) The following documents are filed  as part of this Report:

1) Financial Statements:

Report of Independent Registered Public Accounting Firm . . . . . . . . . . . . . . . F-1
Consolidated Statements of Operations—For the years ended December 31,

2010, 2009 and 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2
Consolidated Balance Sheets—December 31,  2010 and 2009 . . . . . . . . . . . . . . F-3
Consolidated Statements of Stockholders’  Equity—For the years ended

December 31, 2010, 2009 and 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-4

Consolidated Statements of Cash Flows—For the  years  ended December  31,

2010, 2009 and 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-5
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . F-6

2) Financial Statement Schedules:

Schedule II—Valuation and Qualifying Accounts for the years ended December 31,  2010, 2009
and 2008

All other schedules for which provision is made in  the applicable regulation of  the Securities
and Exchange Commission are not required under the  related instructions  or are inapplicable,
and therefore have been omitted.

3) Exhibits

The exhibits filed as part of this Form 10-K are  listed on the Exhibit Index immediately
preceding such Exhibits, which Exhibit Index is  incorporated herein by reference.

37

(This page has been left blank intentionally.)

Report of Independent Registered Public  Accounting Firm

The Board of Directors and Stockholders of  Axcelis Technologies, Inc.

We  have audited the accompanying consolidated balance sheets of Axcelis  Technologies,  Inc. (the

‘‘Company’’) as of December 31, 2010 and 2009, and  the related consolidated  statements of operations,
stockholders’ equity, and cash flows for  each of the three years  in the period ended December 31,
2010. Our audits also included the financial statement schedule  listed in the index  at Item  15(a). These
financial statements and schedule are  the responsibility of the Company’s management. Our
responsibility is to express an opinion  on  these  financial statements and  schedule based  on our audits.

We  conducted our audits in accordance with the standards  of  the Public Company Accounting
Oversight Board (United States). Those  standards require that we  plan and perform the audit to obtain
reasonable assurance about whether  the  financial  statements are free  of material misstatement.  An
audit includes examining, on a test basis, evidence  supporting the amounts and disclosures  in the
financial statements. An audit also includes assessing the accounting  principles used  and significant
estimates made by management, as well as  evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable  basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects,
the consolidated financial position of  Axcelis Technologies, Inc.  at December 31, 2010 and  2009, and
the consolidated results of its operations and its cash  flows for each  of  the three  years  in the period
ended December 31, 2010, in conformity with U.S. generally accepted accounting principles.  Also, in
our  opinion, the related financial statement schedule,  when considered in relation to the  basic financial
statements taken as a whole, presents fairly in all  material respects the information set forth  therein.

We  also have audited, in accordance with the standards of  the Public Company Accounting

Oversight Board (United States), Axcelis  Technologies, Inc.’s  internal control over  financial  reporting as
of December 31, 2010, based on criteria established in Internal  Control—Integrated Framework issued
by the Committee  of Sponsoring Organizations of the Treadway Commission and our report dated
March 14, 2011 expressed an unqualified  opinion thereon.

/s/ Ernst & Young LLP

Boston, Massachusetts
March 14, 2011

F-1

Axcelis Technologies, Inc.
Consolidated Statements of Operations
(In thousands, except per share amounts)

Revenue

Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties, primarily from SEN . . . . . . . . . . . . . . . . . . . . . . . . . . .

$242,771
32,441
—

$ 98,716
33,917
389

$ 194,275
51,880
4,059

Year Ended December 31,

2010

2009

2008

Cost of revenue

Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gross profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating expenses

Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sales and marketing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
General and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of intangibles and long-lived  assets . . . . . . . . . . . . . .
Amortization of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . .
Restructuring charges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Loss from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other income (expense)

Gain on sale of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity loss of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

275,212

133,022

250,214

168,047
21,327

189,374
85,838

84,185
20,773

104,958
28,064

39,524
27,549
32,132
—
—
—
—

99,205

32,661
25,209
34,087
—
—
—
5,541

97,498

161,310
26,289

187,599
62,615

63,262
44,573
43,056
42,115
46,949
2,624
6,873

249,452

(13,367)

(69,434)

(186,837)

—
—
96
—
(3,990)

(3,894)

1,080
(3,238)
181
(1,676)
(3,516)

(7,169)

—
(3,667)
1,614
(6,744)
(169)

(8,966)

Loss before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(17,261)
312

(76,603)
865

(195,803)
861

Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (17,573) $ (77,468) $(196,664)

Net loss per share

Basic and diluted net loss per share . . . . . . . . . . . . . . . . . . . . . . .

$

(0.17) $

(0.75) $

(1.91)

Shares used in computing basic and diluted net  loss per share

Weighted average common shares outstanding . . . . . . . . . . . . . . .

104,522

103,586

102,739

See accompanying Notes to these Consolidated Financial Statements

F-2

Axcelis Technologies, Inc.
Consolidated Balance Sheets
(In thousands, except per share amounts)

Current assets

ASSETS

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . .

Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property, plant and equipment, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2010

2009

$ 45,743
—
57,888
109,653
15,346

228,630
38,594
107
13,541

$ 45,020
4,918
19,094
114,558
10,016

193,606
40,868
2,245
13,884

$ 280,872

$ 250,603

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Warranty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 36,709
10,597
2,556
—
13,859
4,408

68,129
2,417
4,759

$

9,680
9,267
638
1,499
5,127
3,546

29,757
563
3,884

Commitments and contingencies (Note  16)
Stockholders’ equity

Preferred stock, $0.001 par value, 30,000 shares authorized; none issued  or

outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

—

Common stock, $0.001 par value, 300,000 shares authorized; 105,906  shares

issued  and 105,786 shares outstanding at December 31, 2010;
104,212 shares issued and 104,092 shares outstanding at December  31,
2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treasury stock, at cost, 120 shares at  December 31, 2010 and 2009 . . . . . . . .
Accumulated deficit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated other comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . .

106
493,967
(1,218)
(293,520)
6,232

104
488,321
(1,218)
(275,947)
5,139

205,567

216,399

$ 280,872

$ 250,603

See accompanying Notes to these Consolidated Financial Statements

F-3

Axcelis Technologies, Inc.
Consolidated Statements of Stockholders’ Equity
(In thousands)

Common  Stock

Shares

Amount

Additional
Paid-in
Capital

Accumulated
Other

Total

Treasury Accumulated Comprehensive Stockholders’

Stock

Deficit

Income  (Loss)

Equity

Balance at December 31, 2007 . . . . . . . . . 102,565

$103

$478,726 $(1,218) $

(1,815)

$10,210

$486,006

Comprehensive loss

Net loss . . . . . . . . . . . . . . . . . . . . . . .
Foreign currency translation adjustments
Change in pension . . . . . . . . . . . . . . . . .

Total comprehensive loss . . . . . . . . . .
Exercise of stock options . . . . . . . . . . . . .
Issuance of shares under Employee Stock

Purchase Plan . . . . . . . . . . . . . . . . . .
Forfeiture of restricted common  shares . . .
Issuance of restricted common shares . . . .
Stock-based compensation expense . . . . . .

—
—
—

22

—
—
—

—

388
—
(12) —
—
437
—
—

—
—
—

110

786
—
(785)
4,709

— (196,664)
—
—
—
—

—
25,075
140

—

—
—
—
—

—

—
—
—
—

—

—
—
—
—

(196,664)
25,075
140

(171,449)
110

786
—
(785)
4,709

Balance at December 31, 2008 . . . . . . . . . 103,400
Comprehensive loss

103

483,546

(1,218)

(198,479)

35,425

319,377

Net loss . . . . . . . . . . . . . . . . . . . . . . .
Foreign currency translation adjustments
Change in pension . . . . . . . . . . . . . . .

Total comprehensive loss . . . . . . . . . .
Exercise of stock options . . . . . . . . . . . . .
Issuance of shares under Employee Stock

Purchase Plan . . . . . . . . . . . . . . . . . .
Issuance of restricted common shares . . . .
Stock-based compensation expense . . . . . .

—
—
—

66

302
444
—

—
—
—

1

—
—
—

—
—
—

44

184
(104)
4,651

— (77,468)
—
—

—
— (30,239)
(47)
—

—

—
—
—

—

—
—
—

—

—
—
—

(77,468)
(30,239)
(47)

(107,754)
45

184
(104)
4,651

Balance at December 31, 2009 . . . . . . . . . 104,212
Comprehensive loss

104

488,321

(1,218)

(275,947)

5,139

216,399

Net loss . . . . . . . . . . . . . . . . . . . . . . .
Foreign currency translation adjustments
Change in pension . . . . . . . . . . . . . . .

Total comprehensive loss . . . . . . . . . .
Exercise of stock options . . . . . . . . . . . . .
Issuance of shares under Employee Stock

Purchase Plan . . . . . . . . . . . . . . . . . .
Issuance of restricted common shares . . . .
Issuance of restricted shares in satisfaction
of accrued compensation . . . . . . . . . . .
Stock-based compensation expense . . . . . .

—
—
—

704

280
262

448
—

—
—
—

1

1
—

—
—

—
—
—

— (17,573)
—
—
—
—

—
1,535
(442)

552

637
(201)

570
4,088

—

—
—

—
—

—

—
—

—
—

—

—
—

—
—

(17,573)
1,535
(442)

(16,480)
553

638
(201)

570
4,088

Balance at December 31, 2010 . . . . . . . . . 105,906

$106

$493,967 $(1,218) $(293,520)

$ 6,232

$205,567

See accompanying Notes to these Consolidated Financial Statements

F-4

Axcelis Technologies, Inc.
Consolidated Statements of Cash Flow
(In thousands)

Year Ended December 31,

2010

2009

2008

Cash flows from operating activities

Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjustments to reconcile net loss to net  cash used for operating

$(17,573) $ (77,468) $(196,664)

activities
Undistributed loss of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of intangible assets . . . . . . . . . . . . . . . . . . . . . . .
Accretion of premium on convertible debt . . . . . . . . . . . . . . . . .
Stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of goodwill
Impairment of intangibles and long-lived  assets . . . . . . . . . . . . .
Provision for excess inventory . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash dividend from SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes in operating assets & liabilities

Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . .
Accounts payable & other current liabilities . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . .

—
7,045
—
(1,525)
—
—
4,088
—
—
2,015
—

(38,652)
3,549
(3,469)
32,276
10,601
(1,406)
(2,841)

3,238
7,436
(1,080)
(765)
—
133
4,651
—
—
9,818
—

8,572
26,445
8,131
(11,038)
(8,695)
1,154
(4,474)

Net cash used for operating activities . . . . . . . . . . . . . . . . .

(5,892)

(33,942)

Cash flows from investing activities

Expenditures for property, plant, and equipment . . . . . . . . . . . .
Decrease in restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from sale of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payments related to sale of SEN . . . . . . . . . . . . . . . . . . . . . . . .

(1,403)
7,056

(463)
1,491
— 132,847
— (10,590)

Net cash provided by investing activities . . . . . . . . . . . . . . .

5,653

123,285

Cash flows from financing activities

Repayment of convertible debt . . . . . . . . . . . . . . . . . . . . . . . . .
Financing fees and other expenses . . . . . . . . . . . . . . . . . . . . . .
Proceeds from exercise of stock options . . . . . . . . . . . . . . . . . .
Proceeds from Employee Stock Purchase Plan . . . . . . . . . . . . . .
Net cash provided by (used for) financing activities . . . . . . .
Effect of exchange rate changes on cash . . . . . . . . . . . . . . . . . . . . .

— (83,344)
—
45
184
(83,115)
1,098

(523)
553
569
599
363

3,667
20,947
—
189
2,624
3,287
4,709
42,115
46,949
24,631
2,016

48,644
(6,942)
14,991
(23,330)
(26,151)
(162)
(10,239)

(48,719)

(3,407)
9,624
—
—

6,217

—
—
110
786
896
(4,577)

Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . .
Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . .

723
$ 45,020

7,326
$ 37,694

(46,183)
$ 83,877

Cash and cash equivalents at end of  period . . . . . . . . . . . . . . . . . . .

$ 45,743

$ 45,020

$ 37,694

Cash paid for interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash paid for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non Cash investing and financing activities:

Issuance of restricted common stock in satisfaction of accrued

$
$ 2,286

— $ 3,009
734

$

$
$

3,188
1,064

compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

570

$

— $

—

See accompanying Notes to these Consolidated  Financial Statements

F-5

Axcelis Technologies, Inc.
Notes to Consolidated Financial Statements

Note 1. Nature of Business

Axcelis Technologies, Inc. (‘‘Axcelis’’ or the ‘‘Company’’), is a  worldwide producer of ion

implantation, dry strip and other processing equipment  used  in the fabrication of semiconductor chips
in the United States, Europe and Asia.  In  addition, the Company provides extensive aftermarket
service and support, including spare parts, equipment  upgrades, and  maintenance services to the
semiconductor industry.

Until March 30, 2009, the Company  owned 50% of equity of a joint  venture with Sumitomo Heavy

Industries, Ltd. (‘‘SHI’’) in Japan. This joint  venture, which was known as  SEN  licensed technology
from the Company relating to the manufacture of specified  ion implantation products and had  exclusive
rights to manufacture and sell these products in the  territory  of Japan. On March 30, 2009, the
Company sold to SHI all of the Company’s common shares in SEN. in exchange for a cash payment of
13 billion Yen, which resulted in proceeds  of  approximately $132.8  million before advisor fees and
other expenses of $10.6 million. The  sales price was determined through an arm’s length negotiation.
This transaction terminated all prior agreements among the  three parties  relating to the SEN joint
venture. In addition, the arbitration with  SEN initiated by Axcelis in Tokyo was dismissed. Detailed
information about the Company’s investment in SEN is provided in Note 19.

A portion of the proceeds of the sale  were used to pay off, in full, the amounts due to the holder

of the Company’s 4.25% Convertible Senior Subordinated Notes.

Note 2. Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Axcelis and its wholly-owned,

controlled subsidiaries. All intercompany balances and transactions have  been eliminated  in
consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with generally  accepted

accounting principles requires management to make estimates and assumptions that affect the  amounts
reported in the consolidated financial statements and accompanying notes. Actual results could differ
from those estimates.

Foreign Currency

The functional currency for substantially all operations outside the United States is the local
currency. Financial statements for these  operations  are translated into United States dollars at year-end
rates as to assets and liabilities and average exchange rates  during  the year as to revenue and expenses.
The resulting translation adjustments are recorded in  stockholders’ equity as an element of
accumulated other comprehensive income (loss). Foreign currency transaction  gains and losses are
included in other income (expense) in the  consolidated statements of operations.

Cash and Cash Equivalents

Cash and cash equivalents consist of  cash on hand  and highly liquid investments with original
maturities of ninety days or less. Cash equivalents consist primarily of money market securities, direct
and indirect U.S. government obligations, commercial paper, and obligations  of U.S. banks.  Cash
equivalents are carried on the balance sheet at fair market value.

F-6

Inventories

Inventories are carried at lower of cost,  determined using the first-in, first-out (FIFO)  method, or

market. The Company periodically reviews its inventories and  makes  provisions  as necessary for
estimated obsolescence or damaged goods  to  ensure values  approximate  lower of cost or market. The
amount of such markdowns is equal  to  the difference  between cost of inventory  and the  estimated
market value based upon assumptions  about future  demands, selling  prices, and market conditions.

Axcelis records an allowance for estimated  excess  inventory. The allowance is determined using
management’s assumptions of materials usage, based on estimates  of demand and  market  conditions. If
actual market conditions become less  favorable  than those projected by  management, additional
inventory write-downs may be required.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. Depreciation is computed using  the

straight-line method. The historical cost of buildings is depreciated  over forty years and machinery and
equipment principally over three to ten  years.  Expenditures for maintenance and repairs  are expensed
as incurred. Expenditures for renewals  and betterments are capitalized.

Impairment of Intangibles and Long-Lived Assets

The Company records impairment losses on  intangibles and long-lived assets when  events and
circumstances indicate that these assets  might not be recoverable. Recoverability is measured  by  a
comparison of the assets’ carrying amount to their expected future  undiscounted  net cash  flows. If such
assets are considered to be impaired,  the impairment  is measured  based on  the amount by which the
carrying  value exceeds its fair value.

In 2008, the Company experienced a significant decline in  its  stock price resulting in a sustained
market capitalization well below book  value. In addition,  the estimated future  total  available  market for
the Company’s products, as published by independent third party  industry  analysts,  was significantly
revised downward in the fourth quarter and the Company experienced a 26% decline (as compared to
aftermarket revenue in the third quarter  of 2008) in  its  aftermarket  business,  reflecting  significant
declines in manufacturers’ capacity utilization. This  fourth  quarter contraction in the industry  led the
Company to revise its short-term and long-term financial forecast. As discussed in  Note 6,  8 and  9 to
the consolidated financial statements for the year ended December 31, 2008, the Company  recorded a
total intangible and long-lived asset impairment charge of $46.9  million. This charge  consisted of
writing off the net book value of all its intangibles of $8.3  million,  certain other assets of  $21.1 million
and property, plant and equipment of $17.5 million. As a result of economic conditions,  along with its
stock price below book value, the Company performed a test for recoverability  of its  remaining
long-lived assets at December 31, 2009, concluding that long-lived assets were not impaired. At
December 31, 2010, based on the increased demand for  our products and the increase  in our share
price the Company concluded that no  events or circumstances existed that indicated  that  our long-lived
assets were not recoverable.

Future actual performance could be  materially different from our current forecasts, which could
impact future estimates of undiscounted cash flows and may result  in the impairment of  the carrying
amount of the long-lived assets in the future.  This could be caused by  strategic decisions made in
response to economic and competitive  conditions,  the impact of the economic environment on our
customer base, or a material adverse  change in  the Company’s relationships with  significant customers.
Accordingly, the Company will perform an  impairment analysis  in the future when  circumstances or
events warrant.

F-7

Concentration of Risk

Financial instruments, which potentially expose Axcelis  to  concentrations  of credit risk,  consist
principally of accounts receivable and  cash  equivalents. Axcelis’ customers  consist of semiconductor
manufacturers located throughout the world. Axcelis’  net sales to its  ten largest  customers accounted
for 62.7%, 56.6%, and 51.5% of revenue  in  2010, 2009, and 2008, respectively.

Axcelis performs ongoing credit evaluations of its customers’ financial condition and generally

requires no collateral to secure accounts receivable.  For  selected  overseas  sales, Axcelis requires
customers to obtain letters of credit before product is shipped. Axcelis maintains an allowance for
doubtful accounts based on its assessment  of the collectability of accounts  receivable. The Company
reviews the allowance for doubtful accounts monthly. The  Company does  not  have any  off-balance-
sheet credit exposure related to its customers.

Axcelis’ exposure to market risk for changes  in interest rates relates primarily to cash equivalents.
The primary objective of the Company’s  investment activities is to preserve principal while maximizing
yields without significantly increasing  risk. This  is accomplished by investing in marketable  high
investment grade securities and limiting exposure to any one issue or issuer. The Company  does not
use derivative financial instruments to manage its investment portfolio and does  not  expect operating
results or cash flows to be affected to any significant degree by any change in  market  interest rates.

Some of the components and sub-assemblies included in  the Company’s products are  obtained
either from a sole source or a limited group of suppliers. Disruption to the Company’s supply  source,
resulting either from depressed economic conditions or other  factors, could affect its ability to deliver
products to its customers.

Accumulated Other Comprehensive Income

Comprehensive income is comprised  of two  components,  net loss  and other  comprehensive income.
Other comprehensive income consists  of foreign currency translation adjustments and the effects of the
minimum pension liability. The following table shows  the cumulative components of accumulated other
comprehensive income for the years  ended December 31, 2010,  2009 and  2008:

2010

2009

2008

Foreign currency translation adjustments . . . . . . . . . . . .
Pension benefit adjustment . . . . . . . . . . . . . . . . . . . . . .

$6,323
(91)

(in thousands)
$4,788
351

$35,027
398

Total accumulated other comprehensive income . . . . . .

$6,232

$5,139

$35,425

Fair  Value of Financial Instruments

The carrying amounts of certain of the Company’s financial instruments, including  cash

equivalents, accounts receivable, accounts  payable and other accrued liabilities  approximate fair  value
due to their  short maturities.

Revenue Recognition

The Company’s revenue recognition policy  involves significant  judgment by management. As
described below, the Company considers  a broad  array  of facts and  circumstances  in determining when
to recognize revenue, including contractual  obligations to the customer, the complexity  of the
customer’s post delivery acceptance provisions, payment history, customer  creditworthiness and the
installation process. In the future, if the  post delivery  acceptance provisions  and installation process
become  more complex or result in a materially lower rate of acceptance,  the Company may  have to
revise its revenue recognition policy,  which could delay  the timing of  revenue recognition.

F-8

Axcelis’ system sales transactions are made up of multiple elements, including the  system itself and

elements that are not delivered simultaneously with the system. These undelivered  elements might
include a combination of installation services,  extended warranty  and support and spare parts, all of
which  are covered by a single sales price.  The Company allocates revenue  among  the elements  using
the residual method, in which estimated fair market value is established for all elements  other  than  the
system itself and the remainder of the sales price is allocated  to  the  system.

The value of the undelivered elements includes  (a) the  greater of (i)  the fair value of the

installation or (ii) the portion of the  sales price that will not be received until  the installation is
completed (the ‘‘retention’’) plus (b)  the fair value of all other  undelivered elements.  The amount
allocated to installation is based upon the  fair value of the service performed, including labor, which is
based upon the estimated time to complete the installation at hourly rates, and material components.
The fair value of all other undelivered  elements  is based upon the  price charged when these  elements
are sold  separately. Product revenue  for products  which have  demonstrated market acceptance (legacy
products), generally recognized upon  shipment provided  title and risk  of loss  has passed to the
customer, evidence of an arrangement  exists, prices  are contractually  fixed  or determinable,
collectability is reasonably assured through historical collection results  and  regular credit evaluations,
and there are no uncertainties regarding customer acceptance. Revenue from installation services  is
recognized at the time formal acceptance is received from the customer or, for certain customers, when
both the formal acceptance and retention payment  have been  received. Revenue for other elements is
recognized at the time products are shipped or the related  services are performed.

The Company generally recognizes revenue  for products which  have demonstrated market
acceptance (legacy products) at the time of shipment because the customer’s post-delivery acceptance
provisions and installation process have been established to be routine, commercially  inconsequential
and perfunctory. The majority of Axcelis’ systems are designed and tailored to meet  the customer’s
specifications, as outlined in the contract between  the customer and  Axcelis, which may  be  the Axcelis
standard specification. To ensure that the  customer’s specifications are satisfied,  many customers
request that new systems be tested at  Axcelis’ facilities  prior to shipment, normally with  the customer
present, under conditions that substantially  replicate  the customer’s production  environment and the
customer’s criteria are confirmed to have  been  met. Customers of mature products generally do not
require pre-shipment testing. The Company believes the  risk of  failure to complete  a system installation
is remote. Should an installation not  be  completed successfully, the contractual provisions do not
provide for forfeiture, refund or other  purchase  price concession beyond  those prescribed by the
provisions of the Uniform Commercial Code  applicable  generally to such transactions.

For initial shipments of systems with new technologies or  in the small number  of  instances where

Axcelis is unsure of meeting the customer’s specifications or  obtaining customer  acceptance  upon
shipment of the system, Axcelis will defer the recognition of systems revenue  and related costs  until
written customer acceptance of the system is obtained. This deferral period is generally  within twelve
months of shipment.

Revenue related to maintenance and service contracts is  recognized ratably over  the duration of

the contracts, or based on parts usage,  where  appropriate.  Revenue related to service hours is
recognized when the services are performed.

Product revenue includes revenue from system sales, sales  of spare parts, the spare parts

component of maintenance and service contracts and product upgrades. Service revenue includes the
labor component of maintenance and service  contract amounts  charged for  on-site service personnel.

Shipping and Handling Costs

Shipping and handling costs are included  in cost of  revenue.

F-9

Stock-Based Compensation

The Company recognizes compensation expense for all share-based payments to employees and
directors, including grants of employee  stock options, based  on the grant-date fair value of those  share-
based payments using the Black-Sholes  option  pricing  model, adjusted for expected  forfeitures.  Stock-
based compensation expense is recognized ratably  over the requisite service  period.

See Note 14 for additional information relating  to  stock-based compensation.

Income Taxes

The Company records income taxes using the asset and liability  method. Deferred income tax
assets and liabilities are recognized for  the future tax consequences attributable  to  differences between
the financial statement carrying amounts of existing assets  and liabilities and their respective  income tax
bases, and operating loss and tax credit  carryforwards. The Company’s  consolidated  financial statements
contain certain deferred tax assets which  have arisen  primarily  as a result of operating losses, as well  as
other temporary differences between  financial and tax accounting. The Company establishes a  valuation
allowance if the likelihood of realization  of the deferred tax  assets is reduced based on  an evaluation of
objective verifiable evidence. Significant  management  judgment is required  in determining the
Company’s provision for income taxes, the Company’s deferred tax assets and  liabilities  and any
valuation allowance recorded against  those net deferred tax  assets. The Company  evaluates the  weight
of all available evidence to determine whether it is more  likely than not that some portion or  all  of  the
net deferred income tax assets will not  be  realized.

Income taxes include the largest amount of tax benefit for an uncertain tax position that is more
likely than not to be sustained upon audit based  on the technical merits  of the tax position.  Settlements
with tax authorities, the expiration of  statutes of limitations for particular tax positions, or obtaining
new information on particular tax positions may cause a change  to  the effective tax  rate. The  Company
recognizes accrued interest related to unrecognized tax benefits  as interest expense  and penalties as
operating expense.

Net Loss per Share

Basic earnings per share is computed by  dividing  income  available to common stockholders (the

numerator) by the weighted-average  number of common shares  outstanding (the denominator) for the
period. The computation of diluted earnings  per  share is  similar  to  basic earnings per share, except  that
the denominator is increased to include the number of additional common shares  that  would have been
outstanding if the potentially dilutive  common  shares had been  issued, calculated using  the treasury
stock method.

Because the Company had a net loss  for each  of the years ended December 31,  2010, 2009, and
2008, any common shares related to outstanding stock options,  restricted stock, restricted stock units
and convertible debt have been excluded from the calculation of net loss  per  share because  the effect
would have been anti-dilutive.

Recent  Accounting Pronouncements

In September 2009, the FASB issued a new accounting standard to provide guidance  on revenue

recognition criteria for multiple-element  arrangements. The new accounting standard  modifies the
criteria used to separate elements in  a  multiple-element arrangement  by introducing the concept of best
estimate of selling price, establishing  a  hierarchy of evidence  for determining selling  price (fair value),
requiring the use of relative selling price method  and  prohibiting the use  of  the residual method to
allocate arrangement consideration among units of accounting. The new accounting standard also
expands the disclosure requirements for  all  multiple element arrangements and is  effective

F-10

prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on
or after June 15, 2010 (January 1, 2011 for  a calendar year-end entity).  We believe the  adoption  of the
new accounting standard will not have  a  material impact  on the Company’s future  operating results.

Note 3. Restricted Cash

The components of restricted cash are as follows:

Cash collateralizing standby letters of  credit . . . . . . . . . . . . . . . . . . .
Bank guarantees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Statutory liability deposit

December 31,

2010

2009

(in thousands)
— $1,550
— 5,613
—

$107

$107

$7,163

In addition to guarantees that are cash  collateralized, the  Company has surety  bonds related  to
value added tax claims and refunds in Europe of approximately  $7.2 million at  December 31, 2010 and
standby letters of credit issued under the credit line  of $1.6 million. Restricted  cash is reflected in
current or non-current assets based on  the expiration  of the requirement with the  bank  or counterparty.

Note 4. Accounts Receivable, net

The components of accounts receivable are  as follows:

Trade receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . .

$59,245
(1,357)

$21,484
(2,390)

December 31,

2010

2009

(in thousands)

Note 5. Inventories, net

The components of inventories are as follows:

$57,888

$19,094

December 31,

2010

2009

(in thousands)

Raw materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Work in process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finished goods (completed systems) . . . . . . . . . . . . . . . . . . . .

$ 74,596
29,848
5,209

$ 69,661
27,654
17,243

$109,653

$114,558

When recorded, inventory reserves are intended to reduce the carrying  value  of  inventories to their

net realizable value. The Company establishes  inventory reserves when conditions  exist that indicate
inventory may be in excess of anticipated demand  or is  obsolete based upon assumptions about future
demand for the Company’s products or market conditions. The Company regularly evaluates the ability
to realize the value of inventories based  on a combination of factors including the following: forecasted
sales or usage, estimated product end  of life  dates, estimated  current and future  market value and new
product  introductions. Purchasing and  usage alternatives  are also explored  to  mitigate  inventory
exposure. As of December 31, 2010 and  2009, inventories are  stated net of inventory reserves of

F-11

$27.5 million and $37.0 million respectively.  The  decrease in inventory  reserves  in 2010 is primarily  due
to the disposal of $11.2 million of previously reserved inventory. There were  no material sales of
previously reserved inventory during each of the fiscal years ended December 31,  2010, 2009, and 2008.

Note 6. Property, Plant and Equipment, net

The components of property, plant and equipment are as follows:

December 31,

2010

2009

(in thousands)

Land and buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Machinery and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . .
Construction in process . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 79,754
5,775
621

$ 79,284
5,967
62

Accumulated depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . .

86,150
(47,556)

85,313
(44,445)

$ 38,594

$ 40,868

Depreciation expense was $3.6 million, $3.8  million,  and $8.1 million,  for the  years  ended

December 31, 2010, 2009, and 2008,  respectively. The Company  did not record an  impairment charge
related to property, plant and equipment in 2010 and 2009.  During the  fourth  quarter  of  2008, the
Company recorded an impairment charge  related to property, plant  and equipment of $17.5 million.
(See Impairment of Intangibles and Long-Lived Assets  in Note  2).

Note 7. Goodwill

During  the fourth quarter of 2008, the Company determined that the carrying value of the

Cleaning and Curing product line exceeded its estimated fair value. Therefore, the Company performed
the second step of the impairment test  to determine the implied  value of goodwill. Specifically,  the
Company allocated the estimated fair  value of the Cleaning and Curing product line  as determined in
the first step to recognized and unrecognized  net assets, including allocations  to  intangible  assets such
as developed technologies, in-process  research and development, customer relationships  and trade
names. The result of this analysis indicated that there  was  no remaining implied  value attributable to
goodwill and accordingly, the Company recorded a goodwill impairment charge of $42.1  million, the
entire book value of its goodwill, in the fourth quarter of  2008.

F-12

Note 8. Intangible Assets, net

During  the fourth quarter of 2008, the Company reviewed the recoverability  of intangible assets. In

connection with this analysis, management determined that  there  were no future cash flows  associated
with these assets and therefore no fair  value was ascribed  to  them. As a result,  the Company recorded
a non-cash impairment charge of $8.3 million in  the fourth quarter of 2008.

December 31, 2008

Cost

Accumulated
Amortization

Impairment
of long
lived assets

Net Book
Value

(in thousands)

Developed technology . . . . . . . . . . . . .
Customer list
. . . . . . . . . . . . . . . . . . .
Software licenses . . . . . . . . . . . . . . . . .

$48,030
903
877

$40,550
506
453

$49,810

$41,509

$7,480
397
424

$8,301

$ —
—
—

$ —

Amortization expense for intangible  assets was $0.0  million,  $0.0 million, and  $2.6 million, for  each

of the years ended December 31, 2010, 2009, and 2008,  respectively.

Note 9. Assets Manufactured for Internal  Use

The components of assets manufactured  for internal use, included in amounts reported as  other

assets, are as follows:

December 31,

2010

2009

(in thousands)

Cost
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$16,148
(3,768)

$16,446
(3,820)

$12,380

$12,626

These products are used in-house for  research  and  development, training,  and customer

demonstration purposes. Costs are amortized to expense  over three to five years. Amortization expense
was $3.3 million, $3.8 million, and $11.4 million,  for  the years ended  December 31, 2010, 2009,  and
2008, respectively.

In the fourth quarter of 2008, the Company recorded an impairment charge to other assets of

$21.1 million. The sum of the expected  undiscounted future cash flows  of  the long lived asset group
that included these assets was less than  the carrying amount of the asset group.  The  measure of
impairment for these assets was based upon an analysis of the fair value  compared to the carrying
value as described in Note 2. The Company established the fair value  of  the other assets based upon its
best alternative use, which would be  the sale of these tools as used inventory. The  Company has a
history of used tool sales that supports  a range of fair  value for these assets. The timing  of  the
impairment event in the fourth quarter of  2008 primarily related to the industry downturn and  an
anticipated decrease in future cash flows derived from the  long-lived asset  group that includes these
internal use tools, including significant  change  in the manner in which  other assets were being used
resulting in excess and or idle tools.

F-13

Note 10. Restructuring Charges

The company incurred no restructuring charges for  the year ended December 31, 2010. Changes in

the Company’s restructuring liability,  included in  amounts  reported as  other  liabilities,  for the  year
ended December 31, 2010 are as follows:

Balance at December 31, 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Severance

(in thousands)
$ 297
(126)

Balance at December 31, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 171

In May of 2009, the Company implemented  a reduction in force  of approximately  20 percent of
the Company’s global workforce and  continued cost reduction  initiatives  throughout 2009 related to
planned actions taken by management  to control costs  and improve the focus of  its operations in  order
to sustain future profitability and conserve cash. These reductions in force resulted in  a total charge to
restructuring expense of approximately  $6.1 million  related  to  severance and  related costs, offset  by  the
reversal of $0.6 million of accrued compensation  expenses related to terminated  employees. A charge
to expense of $5.5 million was recorded  through December 31, 2009. Through December 31, 2009,  a
total of $6.5 million was paid, which  included $0.3 million paid in  the fourth  quarter  of 2009.

Changes in the Company’s restructuring  liability,  included in  amounts reported as other liabilities,

for the year ended December 31, 2009  are as follows:

Balance at December 31, 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restructuring expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Severance

(in thousands)

$

746
6,084
(6,533)

Balance at December 31, 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

297

In October of 2008, the Company implemented  a reduction in force  to  further reduce  costs to
mitigate deteriorating industry fundamentals. This reduction in  force resulted in a  restructuring charge
to expense of approximately $3.9 million,  principally for separation and outplacement costs, of which
$3.4 million was recorded in the fourth quarter of 2008 and  the  remainder was recorded  in the first
quarter of 2009. A total of $2.9 million was  paid  through December  31, 2008.

In May 2008, the Company implemented a  reduction in  force in connection with planned actions
taken by management to control costs to provide future profitability and conserve cash. This reduction
in force resulted in a total charge to  expense  of  approximately $3.6  million  principally for separation
and outplacement costs, of which $3.5  million had been recognized as expense through December 31,
2008. The remaining $0.1 million was  recognized in the first quarter of 2009. A total of  $3.4 million
was paid through December 31, 2008.

F-14

Changes in the Company’s restructuring  liability,  included in  amounts reported as other liabilities,

for the year ended December 31, 2008  are  as follows:

Balance at December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restructuring expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Severance

(in thousands)

$

916
6,873
(7,043)

Balance at December 31, 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

746

Note 11. Product Warranty

The Company offers a one to three year warranty  for all of its products, the terms and  conditions

of which vary depending upon the product  sold.  For  all systems sold, the Company accrues a liability
for the estimated cost of standard warranty at the time  of system shipment and defers the  portion of
systems revenue attributable to the fair  value of non-standard warranty.  Costs for non-standard
warranty are expensed as incurred. Factors that  affect the  Company’s warranty liability include  the
number of installed units, historical and  anticipated product  failure rates, material usage  and service
labor costs. The Company periodically assesses  the adequacy of its recorded liability and  adjusts  the
amount as necessary.

Changes in the Company’s product warranty liability are as follows:

Years Ended December 31,

2010

2009

2008

Balance at January 1 (beginning of year) . . . . . . . . . . .
Warranties issued during the period . . . . . . . . . . . . .
Settlements made  during the period . . . . . . . . . . . . .
Changes in estimate of liability for pre-existing

$

726
3,722
(1,923)

(in thousands)
$ 3,530
791
(2,363)

$ 6,245
2,564
(5,419)

warranties during the period . . . . . . . . . . . . . . . . .

188

(1,232)

140

Balance at December 31 (end of year) . . . . . . . . . . . . .

$ 2,713

Amount classified as current
. . . . . . . . . . . . . . . . . .
Amount classified as long-term . . . . . . . . . . . . . . . . .

$ 2,556
157

Total Warranty Liability . . . . . . . . . . . . . . . . . . . .

$ 2,713

$

$

$

726

638
88

726

$ 3,530

$ 3,137
393

$ 3,530

Note 12. Financing Arrangements

Convertible Subordinated Debt

On March 30, 2009, Axcelis used $85  million of the proceeds of its sale of SEN to pay in  full its

outstanding 4.25% Convertible Senior Subordinated Notes which it  had issued  in May 2006.

Bank Credit Facility

On March 12, 2010, the Company amended its existing revolving  credit facility with a bank. The
amended agreement provides for borrowings  up to the lesser of $20 million or specified percentages of
the amounts of qualifying accounts receivable and inventory. The facility has certain  financial covenants
requiring us to maintain minimum levels of  operating results and liquidity. On May 25,  2010 the
Company and its lender agreed to modify  a financial covenant in the  revolving credit facility regarding
maximum allowable quarterly losses.  Based  on current forecasts, we believe we will be in  compliance
with the financial covenants throughout  the remaining term of the facility. Borrowings  made under the

F-15

facility will bear interest at the greater of 6% or  the bank’s prime rate plus 2%. At  no time during the
term of the agreement has the company borrowed against  the facility and $18.4 million was available
for borrowing as of December 31, 2010. The agreement will terminate on March 11, 2011. The
Company is currently in negotiations  with  several banks for a new  revolving credit facility on more
favorable terms than our current credit facility. The Company  expects the new credit facility  to  be  in
place during the second quarter of 2011. The Company has requested and has  been granted a  30 day
extension to its existing credit facility  until April 10, 2011.

Note 13. Defined Contribution Plan

The Company maintains the Axcelis  Long-Term Investment Plan, a defined contribution plan. All

regular employees are eligible to participate  and  may  contribute  up to 35% of their compensation on a
before-tax basis subject to IRS limitations. Highly compensated employees may contribute up to 16%
of their compensation on a before-tax  basis subject to IRS limitations. Through 2008,  the Company
matched employee contributions in an amount equal to the greater  of  (A) 100%  of the employee’s
pre-tax contributions up to one thousand  dollars  or (B)  50% of the employee’s pre-tax contributions,
up to the first 6% of eligible compensation. Under this plan,  approximately  $1.6 million was recognized
as expense for the year ended December  31, 2008. The  Company suspended  matching contributions  in
2009, so no expense was recorded for  this plan in either 2010 or 2009.

Note 14. Stock Award Plans and Stock-Based Compensation

2000 Stock Plan

The Company maintains the Axcelis  Technologies, Inc. 2000  Stock Plan (the ‘‘2000 Plan’’), a stock

award and incentive plan which permits the  issuance  of  options, stock appreciation rights, restricted
stock, restricted stock units, and performance awards  to  selected  employees, directors and  consultants
of the Company. The 2000 Plan originally  reserved 18.5 million shares of common stock for future
grant, which amount was subsequently increased to 33.2  million shares of common  stock.  The 2000
Plan expires in 2012. At December 31, 2010  there were 9.9  million shares of common stock available
for future grant. At December 31, 2010,  stock awards outstanding under the 2000 Plan included stock
options, restricted stock and restricted  stock units.

Expiration of non-qualified stock options or  stock appreciation rights is based  on award

agreements. Non-qualified stock options typically  expire ten years from date of grant,  but, if approved
by the Board of Directors, may have a stated term  in excess of ten years. Incentive  stock  option awards
expire ten years from the date of grant. Generally,  options granted  to  employees terminate  upon
termination of employment. Under the  terms of the  2000 Plan, the exercise  price, determined by the
Board of Directors, may not be less than  the fair market value of a share of the Company’s common
stock on the date of grant. Stock options granted  to  employees generally  vest over a  period of  four
years, while stock options granted to  non-employee members of the Company’s Board  of  Directors
generally vest over a period of 6 months  and, once  vested,  are  not affected  by  the director’s
termination of service to the Company.  The Company settles  stock option exercises with newly issued
common shares.

Generally, unvested restricted stock and  restricted stock unit awards  expire upon termination of
service to the Company. Restricted stock  or restricted  stock unit awards granted  to  employees generally
vest over a period of four years, while  restricted stock  or restricted stock  units granted to members  of
the Company’s Board of Directors generally vest over a  period of six months.  The  Company plans to
settle restricted stock units upon vesting with newly issued common shares.

Under the 2000 Plan, fair market value is defined  as the closing price of a share of the common
stock on the Nasdaq Global Select Market as of  any applicable date, as long  as the Company’s shares
are traded on such exchange.

F-16

Grant-Date Fair Value

For the purpose of valuing stock options, the Company  uses  the  Black-Scholes option pricing
model to calculate the grant-date fair  value of an award. The  fair values of options granted were
calculated using the following estimated weighted-average assumptions:

Years ended December 31,

2010

2009

2008

Weighted-average expected volatility . . . . . . . . . . . .
Weighted-average expected term (in years) . . . . . . .
Risk-free interest rate . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . .

97.8%
6.2

76.5%
5.5
1.5-2.0% 2.1-2.6% 1.6-2.4%
0%

76.5%
5.5

0%

0%

Expected volatility—The Company is responsible for estimating volatility  and has considered a
number of factors when estimating volatility. The  Company’s method of estimating expected volatility
for all stock options granted relies on  a combination of historical and implied volatility. The Company
believes that this blended volatility results in a more accurate estimate of the grant-date fair value of
employee stock options because it more  appropriately reflects the  market’s current expectations  of
future volatility.

Expected term—Weighted average expected  term was calculated using a forward looking lattice

model of the Company’s stock price  incorporating a  suboptimal exercise  factor and  a projected
post-vest forfeiture rate.

Risk-free interest rate—The yield on zero-coupon U.S. Treasury securities for a period that is

commensurate with the expected term  assumption is used as the risk-free  interest rate.

Expected dividend yield—Expected dividend  yield was  not  considered in  the option  pricing formula

since the Company does not pay dividends  and has no current plans to do so  in the future.

Stock-Based Compensation Expense

The Company estimates the fair value  of  stock options using the Black-Scholes valuation model.
The fair value of the Company’s restricted  stock and restricted stock units  is calculated based upon the
fair market value of the Company’s stock at  the date of grant.

The Company uses the straight-line attribution method  to  recognize expense  for stock-based
awards such that the expense associated  with  awards is evenly recognized throughout the period.

The amount of stock-based compensation recognized is based on the value  of the portion of the
awards that are ultimately expected to  vest. The Company estimates forfeitures at the time of grant and
revises them, if necessary, in subsequent  periods if actual forfeitures differ from those estimates. The
term ‘‘forfeitures’’ is distinct from ‘‘cancellations’’ or  ‘‘expirations’’  and represents only the unvested
portion of the surrendered stock-based award. The Company currently expects, based on a historical
analysis, a forfeiture rate of 5% per year, including executive officer awards.

The Company recognized stock-based compensation expense of $4.1 million, $4.7 million and
$4.7 million for the years ended December 31, 2010, 2009 and 2008,  respectively. For 2010, 2009 and
2008, the Company primarily used stock  options in its  annual share-based payment  program.

The benefits of tax deductions in excess of recognized compensation cost is reported  as a financing

cash flow, rather than as an operating cash  flow. Because the Company  does not recognize the  benefit
of tax deductions in excess of recognized  compensation cost due to its cumulative net operating loss
position, this had no impact on the Company’s consolidated statement of  cash flows as of and for the
years ended  December 31, 2010, 2009 and 2008.

F-17

Stock Options

The following table summarizes the stock option activity for the years ended December  31, 2010,

2009 and 2008:

Outstanding at December 31, 2007 . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2008 . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2009 . . . . . . . . . . . . .

Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Options

(in thousands)
11,434
5,333
(20)
(196)
(1,027)

15,524
4,555
(66)
(887)
(1,758)

17,368

5,310
(704)
(333)
(2,693)

Outstanding at December 31, 2010 . . . . . . . . . . . . .

18,948

Exercisable at December 31, 2010 . . . . . . . . . . . . . .

8,443

Options Vested or Expected to Vest at

Weighted
Average
Exercise
Price

$11.65
0.71
5.01
5.42
10.75

8.05
1.11
0.68
1.20
9.73

$ 6.43

1.61
0.79
1.23
18.26

$ 3.70

$ 6.68

Weighted
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value

(years)

(in thousands)

6.91

4.31

$30,171

$ 7,455

December 31, 2010(1) . . . . . . . . . . . . . . . . . . . . .

18,098

$ 3.81

6.90

$26,317

(1) In addition to the vested options, the  Company expects  a portion  of the unvested  options to vest at
some point in the  future. Options expected  to  vest is calculated  by applying an estimated forfeiture
rate to the unvested options.

Of the options outstanding at December  31, 2010,  2009, and 2008, 8,443,  9,335,  and 9,805,
respectively, were vested and exercisable  with a weighted average exercise price  of  $6.68, $11.12, and
$12.13, respectively. The total intrinsic value of options  exercised (i.e.  the difference  between  the
market price at exercise and the price  paid by the  employee  to  exercise the options) for  the years
ended December 31, 2010, 2009 and 2008 was $1.2,  $0.8 and $0.0 million, respectively.

The total fair value of stock options  vested during  the year ended December 31, 2010  was

$1.5 million. As of December 31, 2010, there was $7.8 million of total forfeiture adjusted unrecognized
compensation cost related to non-vested stock options  granted under the 2000 Plan. That cost  is
expected to be recognized over a weighted-average  period of 3.1 years.

Restricted Stock and Restricted Stock  Units

Restricted stock units (‘‘RSUs’’) represent the Company’s unfunded and unsecured promise to
issue shares of the common stock at  a future date, subject to the terms  of  the RSU  Award Agreement
and the 2000 Plan. The purpose of these awards is to assist in  attracting and retaining  highly competent
employees and directors and to act as an incentive in motivating  selected  employees and directors to

F-18

achieve long-term corporate objectives.  These  RSU  awards typically vest over four years for employees
and executive officers. The restricted  stock awards  to  directors typically vest over  six months. The fair
value of restricted stock unit and restricted stock awards is charged to expense  ratably over the
applicable service period.

Changes in the Company’s non-vested restricted stock  and  restricted stock units for the years

ended December 31, 2010, 2009, and  2008 are as follows:

Outstanding at December 31, 2007 . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2008 . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2009 . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2010 . . . . . . . . . . . . . .

Shares/units

(in thousands)
2,110
203
(568)
(133)

1,612
(798)
(210)

604
695
(1,052)
(19)

228

Weighted-Average
Grant Date Fair
Value per Share

$6.22
4.60
6.43
6.28

$5.94
6.04
5.63

$5.90
1.72
3.30
2.94

$5.38

The company’s offers a net share settlement program to offset the  personal  income  tax obligations
of the employee’s  restricted stock vesting. Vesting activity above reflects shares  vested before net  share
settlement. As of December 31, 2010, there  was $0.7 million of  total  forfeiture  adjusted unrecognized
compensation cost related to nonvested restricted  stock and  restricted stock units, which is expected to
be amortized over a weighted average  amortization  period of 0.76 years.

Employee Stock Purchase Plan

The Employee Stock Purchase Plan (the ‘‘Purchase Plan’’) provides effectively all Axcelis
employees the opportunity to purchase  common stock of the  Company at  less  than market prices.
Purchases are made through payroll deductions  of up to 10%  of  the employee’s  salary, subject to
certain caps set forth in the Purchase  Plan.  Employees may purchase Axcelis common  stock  at 85% of
the market value of the Company’s common stock on  the day the stock is purchased.

The Purchase Plan is considered compensatory and as such, compensation expense  has been
recognized based on the benefit of the discounted stock price, amortized  to compensation expense over
each  offering period of six months. Compensation expense for the years ended December 31, 2010,
2009, and 2008 was $0.1 million, $0.0 million, and $0.1 million respectively.

As of December 31, 2010, there were a  total  of 2.7 million shares reserved for issuance and
available for purchase under the Purchase  Plan.  There were  0.3, 0.3, and  0.4  million  shares purchased
under the Purchase Plan for the years ended December 31,  2010, 2009, and 2008 respectively.

Note 15. Stockholders’ Equity

Preferred Stock

The Company may issue up to 30 million shares of preferred stock in  one or more series.  The

Board of Directors is authorized to fix the  rights and terms for any series of preferred  stock without

F-19

additional shareholder approval. As of  December  31, 2010 and 2009, there were  no outstanding shares
of preferred stock.

Note 16. Commitments and Contingencies

Lease Commitments

The Company leases manufacturing and office facilities and certain equipment under operating

leases that expire through 2016. Rental  expense  was $5.2 million, $5.7  million, and $6.9 million under
operating leases. Future minimum lease  commitments  on non-cancelable  operating leases are  as
follows:

Year ended December 31,

2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Operating
Leases

(in thousands)
$2,955
1,916
1,483
1,310
1,027
947

$9,638

Purchase Commitments

The Company has non-cancelable contracts and purchase orders for inventory of $59.0  million  at

December 31, 2010.

Litigation

The Company is not presently a party to any litigation  that it  believes  might have a  material
adverse effect on its business operations.  The Company is, from time to time, a party  to  litigation  that
arises in  the normal course of its business operations.

Indemnifications

The Company’s system sales agreements typically include provisions under  which the Company
agrees to take certain actions, provide  certain remedies and defend its customers  against third-party
claims of intellectual property infringement under specified conditions and to indemnify customers
against any damage and costs awarded  in connection with  such claims. The Company has not incurred
any material costs  as a result of such indemnifications and has not accrued any  liabilities  related to
such obligations in the accompanying  consolidated  financial  statements.

Note 17. Business  Segment, Geographic Region Information, and Significant  Customers

Axcelis operates in one business segment, which  is the manufacture  of capital equipment  for the

semiconductor manufacturing industry. The  principal  market  for  semiconductor manufacturing
equipment is semiconductor manufacturers. Substantially all sales are made directly by Axcelis  to
customers located in the United States, Europe and Asia Pacific.

Axcelis’ ion implantation systems product  line  includes high current, medium  current and high
energy implanters. Other products include  dry  strip equipment, curing systems, and thermal processing
systems. In addition to equipment, Axcelis  provides post-sales  equipment service and  support, including
spare parts, equipment upgrades, maintenance services and customer training.

F-20

Revenue by product lines is as follows:

Ion implantation systems, services, and royalties . . .
Other products systems, services, and royalties . . . .

$232,335
42,877

(in thousands)
$110,946
22,076

$204,886
45,328

$275,212

$133,022

$250,214

Years ended December 31,

2010

2009

2008

Revenue and long-lived assets by geographic region,  based on the physical  location of the

operation recording the sale or the asset, are as  follows:

2010
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asia Pacific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2009
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asia Pacific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2008
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asia Pacific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Revenue

Long-Lived
Assets

(in thousands)

$190,819
33,822
50,571

$50,532
—
442

$275,212

$50,974

$ 83,790
23,063
26,169

$53,494
—
—

$133,022

$53,494

$175,041
29,605
45,568

$56,083
—
—

$250,214

$56,083

Long-lived assets consist of property, plant and equipment, net  and assets manufactured  for

internal use. Operations in Europe and Asia Pacific consist of sales and service  organizations.

International revenue, including export sales from  U.S. manufacturing facilities  to  foreign

customers, sales by foreign subsidiaries and branches, and royalties was $208.5 million (75.8% of total
revenue) in 2010, $83.5 million (62.8%  of total revenue) in 2009,  and $161.9 million  (64.7%  of total
revenue) in 2008.

One  customer accounted for 18.6% of consolidated revenue  and two customers accounted for
30.2% and 10.4% of consolidated accounts receivable, respectively at December 31,  2010. No customer
accounted for more than 10% of consolidated revenue or consolidated accounts receivable at
December 31, 2009. One customer accounted for 11.7% of  revenue and 12.0% of consolidated accounts
receivable at December 31, 2008.

F-21

Note 18. Income Taxes

Loss before income taxes is as follows:

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity income (loss) of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Years ended December 31,

2010

2009

2008

(in thousands)
$(21,526) $(78,185) $(193,451)
1,315
4,820
(3,667)
(3,238)

4,265
—

Loss before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(17,261) $(76,603) $(195,803)

Income taxes (credits) are as follows:

Years ended December 31,

2010

2009

2008

(in thousands)

Current:

United States

Federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ — $
309
1528

5
99
1,526

$

8
136
528

Total current

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,837

1,630

672

Deferred:

Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(1,525)

Total deferred . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(1,525)

(765)

(765)

189

189

Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

312

$ 865

$861

Reconciliations of income taxes at the United States Federal statutory  rate to the  effective income

tax rate are as follows:

Years ended December 31,

2010

2009

2008

Income credit at the United States statutory rate . . . . . . . . . . . . . . . . .
State income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of goodwill
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unrecognized tax benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unremitted earnings of foreign subsidiaries . . . . . . . . . . . . . . . . . . . . .
Effect of change in valuation allowance . . . . . . . . . . . . . . . . . . . . . . . .
Foreign income tax rate differentials . . . . . . . . . . . . . . . . . . . . . . . . . .
Restoration of foreign deferred tax assets . . . . . . . . . . . . . . . . . . . . . .
Equity loss of SEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Taxable gain on sale of investment in SEN . . . . . . . . . . . . . . . . . . . . .
Deemed distribution from foreign subsidiaries . . . . . . . . . . . . . . . . . . .
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(in thousands)
$(6,041) $(26,812) $(68,531)
136
14,740
—
5,965
45,586
68
—
1,283
—
—
1,614

99
—
—
705
(21,446)
(926)
—
1,133
41,973
3,914
2,225

309
—
842
—
6,550
(1,490)
(1,329)
—
—
2,152
(681)

Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

312

$

865

$

861

F-22

Significant components of current and  long-term deferred income taxes  are as  follows:

Federal net operating loss carryforwards . . . . . . . . . . . . .
State net operating loss carryforwards . . . . . . . . . . . . . . .
Foreign net operating loss carryforwards . . . . . . . . . . . . .
Federal tax credit carryforwards . . . . . . . . . . . . . . . . . . .
State tax credit carryforwards . . . . . . . . . . . . . . . . . . . . .
Unremitted earnings of foreign subsidiaries . . . . . . . . . . .
Intangible assets
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property, plant and equipment . . . . . . . . . . . . . . . . . . . .
Accrued compensation . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Warranty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,

2010

2009

Current

Long Term

Current

Long Term

(in thousands)

$

— $ 75,459
2,812
—
1,723
—
15,087
—
9,205
—
(1,589)
—
898
82
6,627
—
—
1,642
—
17,519
4,038
—
57
938
3,914
74

$

— $ 58,261
2,058
—
3,435
—
15,954
—
10,535
—
(6,670)
—
1,084
87
6,752
—
—
1,549
—
34,777
3,422
—
32
238
3,930
892

Deferred taxes, gross . . . . . . . . . . . . . . . . . . . . . . . . . . .

20,255

118,231

37,543

98,793

Valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(18,174)

(116,723)

(35,464)

(98,809)

Deferred taxes, net

. . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 2,081

$

1,508

$ 2,079

$

(16)

At December 31, 2010, the Company had $138.5 million of deferred tax assets relating to net
operating loss carryforwards, tax credit  carryforwards and other temporary differences, which are
available to reduce income taxes in future  years.  A valuation allowance must be established  when it is
‘‘more likely than not’’ that all or a portion  of  deferred tax assets will  not  be  realized. A review of all
available positive and negative evidence  needs to be considered, including a company’s  performance,
the market environment in which the company operates length  of carryback and carryforward  periods,
existing sales backlog, and projections  of  future  operating results. Where there are cumulative losses in
recent years there is a strong presumption that a valuation allowance is needed.  This presumption  can
be overcome in very limited circumstances.

The Company is in a three year cumulative  loss position in the  United States. As a result,  the
Company maintains a 100% valuation allowance for  entities  in those  tax  jurisdictions to reduce the
carrying  value of deferred tax assets to  zero. The  Company will continue to maintain a  full valuation
allowance for those tax assets until sustainable future levels  of profitability  are evident.

Changes in the valuation allowance in 2010 and 2009  were  attributable  to  changes in the
composition of temporary differences  and changes  in net operating loss  carryforwards. In addition,
during 2010 the Company performed  an  evaluation  of  the deferred tax  assets of certain of its foreign
subsidiaries. Based on the subsidiaries  recent and expected ability  to  generate  taxable income, the
Company reduced the subsidiary’s corresponding valuation allowance and recognized a tax benefit of
$1.3 million.

At December 31, 2010, the Company has federal and state net operating  loss carryforwards of
approximately $217.3 million and foreign net operating  loss carryforwards of approximately $9.3  million
expiring principally between 2021 and 2030.

The Company has research and development and other tax  credit carryforwards of approximately

$18.7 million at December 31, 2010 that can be used to reduce future federal and  state income tax
liabilities. These tax credit carryforwards expire  principally between 2021  and 2028.  In  addition, the

F-23

Company has foreign tax credit carryforwards of  approximately $5.6 million  at December 31, 2010  that
are available to reduce future U.S. income tax liabilities subject to certain  limitations. These foreign tax
credit carryforwards expire between 2012 and 2016.

The Company and its subsidiaries file income tax returns in  the U.S. federal jurisdiction and
various states and foreign jurisdictions. The Company and most foreign  subsidiaries are subject to
income tax examinations by tax authorities  for all years dating  back to 2001. The  Company’s policy is to
recognize interest related to unrecognized tax benefits as  interest  expense and penalties as operating
expenses. The Company believes that it  has appropriate  support for the income tax  positions  taken and
to be taken on its tax returns and that  its accruals for tax liabilities are adequate for all open years
based on an assessment of many factors including past experience  and interpretations of tax law applied
to the facts of each matter.

At December 31, 2010, the Company had unrecognized tax benefits  of approximately  $7.0 million,

of which approximately $4.7 million reduced the  Company’s deferred  tax  assets and the offsetting
valuation allowance and $2.2 million was  recorded  in other  long-term  liabilities. The Company does not
expect any significant changes in unrecognized tax benefits in  2011.

A reconciliation of the beginning and  ending balance of unrecognized tax  benefits is  as follows:

Balance at beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Increases in unrecognized tax benefits  as a result of tax positions taken  during a

prior period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Increases in unrecognized tax benefits  as a result of tax positions taken  during the

current period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2010

2009

(in thousands)

$5,934

$5,824

189

842

110

—

Balance at end of  year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$6,965

$5,934

Recorded as other long-term liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recorded as a decrease in deferred tax assets and offsetting valuation allowance . . . .

$2,246
4,719

$1,302
4,632

$6,965

$5,934

Note 19. SEN

Until March 30, 2009, the Company  owned 50%  of the equity of a joint venture with Sumitomo

Heavy Industries, Ltd. (‘‘SHI’’) in Japan. This joint  venture, which was known as SEN was  established
in 1982 and licensed technology from  the  Company relating to the manufacture of specified ion
implantation products and had exclusive rights to manufacture  and sell these products in the  territory
of Japan. On March 30, 2009, pursuant  to  a Share Purchase Agreement  dated February 26, 2009,  the
Company sold to SHI all of the Company’s  common shares in SEN in exchange for a cash payment of
13 billion Yen, which resulted in proceeds of approximately $132.8  million before advisor fees and
other expenses of $10.6 million. The  sales price was determined through an arm’s length negotiation.
This transaction terminated all prior agreements among the  three parties  relating to the SEN joint
venture. In addition, an arbitration the Company  had  initiated  against SEN in  Tokyo was dismissed.

In connection with the sale of the Company’s investment in SEN, on March 30, 2009, the

Company and SEN entered into a License Agreement pursuant to which  the parties have  cross licensed
each  other to use certain ion implant patents and technical  information on a  non-exclusive,  perpetual,
royalty-free, worldwide basis, provided that both  received  sole  exclusive  licenses for 4  years  in the U.S.
and Japan, respectively. The licenses to  technical information cover  only technical information shared
by the parties prior to the date of the  license, so  the license to SEN does not cover technical
information relating to the Optima HD  and Optima XE. The license also  excludes  patents  relating to
the Company’s work in molecular implant and certain patents developed  for the Optima  HD  and

F-24

Optima XE. The parties provided each  other with limited warranties  regarding their right to grant
these licenses, and indemnity with respect  thereto,  but disclaim any warranty regarding the  validity  or
freedom from infringement of the licensed intellectual property. Neither party  will  provide any  support
for the other party’s use of the licensed  intellectual property.

The sale of the Company’s investment in SEN on March 30,  2009, resulted  in a gain of

approximately $1.1 million. This gain includes net proceeds of $122.2 million (after payment of advisor
fees and other costs of $10.6 million) and cumulative foreign translation gain of $23.5 million,
previously recorded in other comprehensive income, reduced by  the carrying  value of  the investment on
the date of sale of $144.6 million. The  gain from  the sale of the Company’s investment in  SEN  is
recorded  in other income.

Note 20. Quarterly Results of Operations (unaudited)

Dec. 31,
2010

Sept. 30,
2010

June 30, March 31,

2010

2010

Dec. 31,
2009

Sept. 30,
2009

June 30, March  31,

2009

2009

(in thousands, except per share data)

Revenue . . . . . . . . . . . . $93,403 $75,106 $58,203 $ 48,500 $ 38,737 $ 35,007 $ 33,550 $ 25,728
3,007
Gross profit . . . . . . . . . .
Net income (loss) . . . . . .
(29,155)
Net income (loss) per

13,007
(11,101)

5,886
(22,379)

7,820
(15,898)

11,351
(10,036)

19,868
(4,529)

21,470
(6,273)

31,493
4,330

share basic and diluted $

0.04 $ (0.06) $ (0.04) $

(0.11) $

(0.10) $

(0.15) $

(0.22) $

(0.28)

Results of operations for the quarters ended  September 30, 2009, June 30, 2009 and March 31,

2009 included restructuring charges of  $0.4 million, $4.1 million  and $1.0  million  respectively.

Results of operations for the quarter  ended December 31, 2010 include a tax benefit of

$1.3 million related to the restoration of  deferred  tax  assets in certain foreign jurisdictions.

F-25

Pursuant to the requirements of Section 13  or 15(d) of the Securities Exchange Act of 1934, the

Registrant has duly caused this report to be signed on its  behalf  by the undersigned,  thereunto duly
authorized.

Signatures

AXCELIS TECHNOLOGIES, INC.

By: /s/ MARY G. PUMA

Dated: March 14, 2011

Mary G. Puma, Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by

the following persons on behalf of the Registrant  and in the capacities and on the  date indicated.

Signature

Title

Date

/s/ MARY G. PUMA

Mary G. Puma

/s/ JAY ZAGER

Jay Zager

/s/ R. JOHN FLETCHER

R. John Fletcher

/s/ STEPHEN R. HARDIS

Stephen R. Hardis

/s/ WILLIAM C. JENNINGS

William C. Jennings

/s/ PATRICK H. NETTLES

Patrick H. Nettles

/s/ H. BRIAN THOMPSON

H. Brian Thompson

/s/ GEOFFREY WILD

Geoffrey Wild

/s/ EDWARD H. BRAUN

Edward H. Braun

Director and Principal Executive Officer

March 14, 2011

Principal Accounting and Financial Officer March 14, 2011

Director

Director

Director

Director

Director

Director

Director

March 14, 2011

March 14, 2011

March 14, 2011

March 14, 2011

March 14, 2011

March 14, 2011

March 14, 2011

Exhibit No.

Exhibit Index

Description

3.1

3.2

4.1

10.1*

10.2*

10.3

10.4*

10.5*

10.6*

10.7*

10.8*

Amended and Restated Certificate of Incorporation of the registrant,  as adopted May  6,
2009. Incorporated by reference to Exhibit  3.1 of the Company’s Form  8-K  filed with the
Commission on May 11, 2009.

Bylaws of the Company, as  amended  as  of  August  8, 2007. Incorporated by reference  to
Exhibit 3.2 of the Company’s Form 10-Q for the quarter ended June 30,  2007, filed with
the Commission on August 9, 2007.

Specimen Stock Certificate.  Incorporated by reference to Exhibit 4.1 of the Company’s
Registration Statement on Form S-1 (Registration No. 333-36330).

Axcelis Technologies, Inc.  2000 Stock Plan, as amended through June  23, 2005.
Incorporated by reference to Exhibit 10.2 to the Company’s Current Report  on Form 8-K
filed with the Commission on June 28,  2005.

Axcelis Management Incentive Plan, as amended and restated by the Compensation
Committee of the  Board of Directors on February  11, 2010. Incorporated by reference to
Exhibit 10.2 of the Company’s report on Form 10-K for the year ended December 31, 2009
filed with the Commission on March 15,  2010.

Form of Indemnification Agreement entered into by  the Company with  each of its directors
and executive officers. Incorporated by reference  to  Exhibit 10.2 of the Company’s
Registration Statement on Form S-1 (Registration No. 333-36330).

Form of Change in Control  Agreement,  as  approved by the Board of Directors  on
October 16, 2007 and first effective on November 6, 2007, between the Company and each
of its executive officers. Incorporated by reference  to  Exhibit 10.4 of the  Company’s report
on Form 10-Q for the quarter ended September 30,  2007  filed with the Commission on
November 8, 2007.

Form of Employee non-qualified stock option grant under the 2000 Stock Plan, updated as
of April 5, 2002. Incorporated by reference to Exhibit  10.1 of the Company’s report on
Form 10-Q filed with the Commission on November 9, 2004.

Form of Non-Employee Director  stock non-qualified  stock option grant under the  2000
Stock Plan, updated as of July 12, 2004.  Incorporated  by reference to Exhibit 10.2 of the
Company’s report on Form 10-Q filed with the Commission on November 9, 2004.

Form of Restricted Stock Agreement for use under the 2000 Stock Plan. Incorporated by
reference to Exhibit 10.4 to the Company’s  Current Report on Form 8-K filed with the
Commission on June 28, 2005.

Form of Restricted Stock Unit Award  Agreement  for use under  the 2000 Stock Plan.
Incorporated by reference to Exhibit 10.3 to the Company’s Current Report  on Form 8-K
filed with the Commission on June 28,  2005.

10.9*

Named Executive Officer Base  Compensation  at March 14, 2011. Filed herewith.

10.10*

Non-Employee Director Cash Compensation at March  14, 2011. Filed herewith.

10.11*

Amended and Restated Employment Agreement between the Company and Mary  G. Puma
dated November 6, 2007. Incorporated by reference to Exhibit 10.3 of the Company’s
report on Form 10-Q for the quarter  ended September  30,  2007 filed with the  Commission
on November 8, 2007.

Exhibit No.

10.12*

10.13

10.14

10.15

10.16

14.1

21.1

23.1

31.1

31.2

32.1

32.2

Description

Letter from Mary G. Puma  to  the Board  of  Directors dated  May 1,  2009, modifying  her
Amended and Restated Employment  Agreement with the  Company. Incorporated by
reference to Exhibit 10.1 of the Company’s report on Form 8-K  filed with the Commission
on May 11, 2009.

Amended and Restated Loan and Security Agreement dated as of March 12, 2010 between
the Company and Axcelis Technologies CCS Corporation, as borrowers, and Silicon Valley
Bank. Incorporated by reference to Exhibit 10.1 to the Company’s report  on Form 10-Q for
the quarter ended March 31, 2010 filed  with the Commission on May 12, 2010.

Export-Import Loan and Security Agreement dated as of March 12,  2010 between the
Company and Axcelis Technologies CCS Corporation, as  borrowers, and Silicon Valley
Bank. Incorporated by reference to Exhibit 10.1 to the Company’s report  on Form 10-Q for
the quarter ended March 31, 2010 filed  with the Commission on May 12, 2010.

First Loan Modification Agreement entered into as of May 25, 2010 among the Company,
Axcelis Technologies CCS Corporation and Silicon  Valley  Bank. Incorporated by reference
to Exhibit 10.1 to the Company’s report on Form 8-K filed with the Commission on
May  27, 2010.

License Agreement dated  as of March 30, 2009 between the  Company and SEN
Corporation. Incorporated by reference to Exhibit 10.1 to the  Company’s Current Report
on Form 8-K filed  with the Commission  on April 3, 2009.

Ethical Business Conduct at  Axcelis, revised through January 2003. Incorporated by
reference to Exhibit 14.1 of the Company’s report on Form 10-K  filed with the Commission
on March 28, 2003.

Subsidiaries of the Company.  Filed herewith.

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. Filed
herewith.

Certification of the Principal  Executive Officer under Exchange Act
Rule 13a-14(a)/15d-14(a) (Section 302  of  the Sarbanes-Oxley Act), dated March 14, 2011.
Filed herewith.

Certification of the Principal  Financial Officer  under Exchange Act
Rule 13a-14(a)/15d-14(a) (Section 302  of  the Sarbanes-Oxley Act), dated March 14, 2011.
Filed herewith.

Certification of the Principal  Executive Officer pursuant to Section 1350 of Chapter  63 of
title 18 of the United States Code (Section 906  of the Sarbanes-Oxley Act), dated
March 14, 2011. Filed herewith.

Certification of the Principal  Financial Officer  pursuant to Section  1350 of Chapter 63 of
title 18 of the United States Code (Section 906  of the Sarbanes-Oxley Act), dated
March 14, 2011. Filed herewith.

*

Indicates a management contract or compensatory plan.

You may obtain a copy of any of these  exhibits  free of charge either on  our  website at
http://www.axcelis.com or by contacting  Investor  Relations at  Axcelis Technologies,  Inc., 108 Cherry Hill
Drive, Beverly, MA 01915-1053.

Schedule II—Valuation and Qualifying  Accounts
Axcelis Technologies, Inc.
(In thousands)

Balance at
Beginning of
Period

Charged to
Costs and
Expenses

Deductions Other(*)

Balance  at
End of
Period

Year Ended December 31, 2010
Allowance for doubtful accounts and returns . .
Reserve for excess and obsolete inventory . . . .

Year Ended December 31, 2009
Allowance for doubtful accounts and returns . .
Reserve for excess and obsolete inventory . . . .

Year Ended December 31, 2008
Allowance for doubtful accounts and returns . .
Reserve for excess and obsolete inventory . . . .

$ 2,390
36,980

$ (1,120)
2,015

$
(17)
(11,224)

$ 104
(254)

$ 1,357
27,517

$ 2,545
47,656

$

(88)
9,818

$

— $ (67)
238

(20,732)

$ 2,390
36,980

$ 2,927
25,071

$

308
24,631

$

(691)
(2,596)

$

1
550

$ 2,545
47,656

(*) Represents foreign currency translation adjustments.

STOCK PERFORMANCE GRAPH
This graph compares the five-year cumulative total stockholder returns for our common stock to that of the Philadelphia Semiconductor Index and the Nasdaq
Composite Index at each of the last five fiscal year ends. The cumulative returns are based on a $100 investment on December 31, 2005, with all dividends, if
any, being reinvested. The stock performance shown on the graph below is not necessarily indicative of future price performance.

Company/Index Name

Axcelis Technologies Inc.
NASDAQ Composite Index
Philadelphia Semiconductor Index

December 31
2005
$100.00
$100.00
$100.00

December 31
2006
$122.22
$109.52
$97.59

December 31
2007
$96.44
$120.27
$85.10

December 31
2008
$10.69
$70.32
$44.06

December 31
2009
$29.56
$102.89
$75.06

December 31
2010
$72.54
$120.29
$85.89

BOARD OF DIRECTORS

EXECUTIVE OFFICERS

Edward H. Braun
Chairman,
Veeco Instruments, Inc.

R. John Fletcher
Chief Executive Officer, 
Fletcher Spaght, Inc.

Stephen R. Hardis
Lead Director, Axcelis Technologies, Inc.,
Retired Chairman and Chief Executive Officer,
Eaton Corporation

William C. Jennings
Retired Partner, PricewaterhouseCoopers LLP

Patrick H. Nettles
Executive Chairman of the Board of Directors, 
CIENA Corporation

Mary G. Puma
Chairman and Chief Executive Officer, 
Axcelis Technologies, Inc.

Mary G. Puma
Chairman and Chief Executive Officer

Jay Zager
Executive Vice President and Chief Financial Officer

Stephen G. Bassett
Executive Vice President, Finance

William Bintz
Senior Vice President, Marketing

Kevin J. Brewer
Executive Vice President, Operations

Lynnette C. Fallon
Executive Vice President, Human Resources and Legal, 
General Counsel and Secretary

Matthew P. Flynn
Executive Vice President, Global Customer Operations

H. Brian Thompson
Executive Chairman, 
Global Telecom & Technology

Geoffrey Wild
Chief Executive Officer,
AZ Electronic Materials plc

AUDIT COMMITTEE
William C. Jennings, Chairman
R. John Fletcher
Geoffrey Wild

COMPENSATION COMMITTEE
H. Brian Thompson, Chairman
R. John Fletcher
Stephen R. Hardis

NOMINATING AND GOVERNANCE 
COMMITTEE
Patrick H. Nettles, Chairman
Stephen R. Hardis

ANNUAL MEETING DATE & LOCATION
The annual meeting of stockholders will be held at 10:30 a.m. 
on Tuesday, April 26, 2011 at Axcelis corporate headquarters.

CORPORATE HEADQUARTERS
108 Cherry Hill Drive
Beverly, MA 01915-1053
978-787-4000

INDEPENDENT AUDITORS
Ernst & Young LLP
200 Clarendon Street
Boston, MA  02116-5072

INVESTOR INFORMATION/SEC FORM 10-K
Information on the Company, as well as the Company’s 2010
Annual Report on SEC Form 10-K and other SEC filings, can be
obtained free of charge either on our website at
http://www.axcelis.com or by contacting Investor Relations 
at Axcelis Technologies, Inc., 108 Cherry Hill Drive, Beverly, MA
01915-1053.  You can also e-mail investor relations at 
investor.relations@axcelis.com.

LEGAL COUNSEL
Edwards Angell Palmer & Dodge LLP
111 Huntington Avenue at Prudential Center
Boston, MA 02108-3190

STOCK LISTING
The Company's common stock is traded on the NASDAQ Global
Select market under the symbol ACLS.

TRANSFER AGENT & REGISTRAR
For questions regarding misplaced stock certificates, changes
of address, or the consolidation of accounts, please contact the
Company's transfer agent:

Telephone: 1-781-575-2725
Hearing Impaired TDD#:  1-800-952-9245

Website:
http://www.computershare.com 

Address:
Computershare Trust Company, N.A. 
P.O. Box 43078
Providence, RI 02940-3078

Private Couriers/Registered Mail:
Computershare Trust Company, N.A. 
250 Royall Street
Canton, MA 02021

WEBSITE
http://www.axcelis.com

SAFE HARBOR STATEMENT
This document contains forward-looking statements under the SEC safe harbor provisions.  These statements are based on management’s current expectations and should be
viewed  with  caution.    They  are  subject  to  various  risks  and  uncertainties,  many  of  which  are  outside  the  control  of  the  company,  including  our  ability  to  implement 
successfully  our  profit  plans,  the  continuing  demand  for  semiconductor  equipment,  relative  market  growth,  continuity  of  business  relationships  with  and  purchases  by 
major  customers,  competitive  pressure  on  sales  and  pricing,  increases  in  material  and  other  production  costs  that  cannot  be  recouped  in  product  pricing  and  global 
economic and financial conditions.